<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003718.pub4" GROUP_ID="MENSTR" ID="380201032900035079" MERGED_FROM="639499081814593522" MODIFIED="2015-05-01 01:12:25 +0100" MODIFIED_BY="Helen Nagels" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-04-20 10:44:17 +1200" NOTES_MODIFIED_BY="Helen E Nagels" REVIEW_NO="NJ212" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.1">
<COVER_SHEET MODIFIED="2015-05-01 01:12:25 +0100" MODIFIED_BY="Helen Nagels">
<TITLE MODIFIED="2015-04-16 15:43:29 +1200" MODIFIED_BY="Helen E Nagels">Tubal flushing for subfertility</TITLE>
<CONTACT MODIFIED="2015-05-01 01:12:25 +0100" MODIFIED_BY="Helen Nagels"><PERSON ID="95151163560867436189090824004506" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lamiya</FIRST_NAME><LAST_NAME>Mohiyiddeen</LAST_NAME><POSITION>Consultant in Reproductive Medicine</POSITION><EMAIL_1>Lamiya.Mohiyiddeen@cmft.nhs.uk</EMAIL_1><ADDRESS><ORGANISATION>St Mary's Hospital</ORGANISATION><ADDRESS_1>Oxford Road</ADDRESS_1><CITY>Manchester</CITY><ZIP>M13 9WL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-05-01 01:12:25 +0100" MODIFIED_BY="Helen Nagels"><PERSON ID="95151163560867436189090824004506" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lamiya</FIRST_NAME><LAST_NAME>Mohiyiddeen</LAST_NAME><POSITION>Consultant in Reproductive Medicine</POSITION><EMAIL_1>Lamiya.Mohiyiddeen@cmft.nhs.uk</EMAIL_1><ADDRESS><ORGANISATION>St Mary's Hospital</ORGANISATION><ADDRESS_1>Oxford Road</ADDRESS_1><CITY>Manchester</CITY><ZIP>M13 9WL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="43642514760345681988100305024548" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Hardiman</LAST_NAME><POSITION>SHO</POSITION><EMAIL_1>anniehardiman@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of O &amp; G</DEPARTMENT><ORGANISATION>Royal Bolton Hospital</ORGANISATION><CITY>Bolton</CITY><ZIP>BL4 0JR</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="93879136075949887248110831234619" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cheryl</FIRST_NAME><LAST_NAME>Fitzgerald</LAST_NAME><EMAIL_1>Cheryl.Fitzgerald@cmft.nhs.uk</EMAIL_1><ADDRESS><ORGANISATION>St Mary's Hospital</ORGANISATION><CITY>Manchester</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="5323" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Edward</FIRST_NAME><LAST_NAME>Hughes</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>hughese@mcmaster.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>McMaster University, REI Consultant, ONE Fertility</ORGANISATION><ADDRESS_1>1200 Main Street West</ADDRESS_1><ADDRESS_2>Room 4D14</ADDRESS_2><CITY>Hamilton</CITY><ZIP>L8N 3Z5</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+905 634 4440</PHONE_1><FAX_1>+1 905 577 0471</FAX_1></ADDRESS></PERSON><PERSON ID="422DFBB182E26AA200991D56892EC1A4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ben Willem</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Mol</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor of Obstetrics and Gynecology</POSITION><EMAIL_1>ben.mol@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>The Robinson Institute, School of Paediatrics and Reproductive Health</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><ADDRESS_1>Level 3, Medical School South Building</ADDRESS_1><ADDRESS_2>Frome Road</ADDRESS_2><CITY>Adelaide</CITY><ZIP>SA 5005</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 434122170</PHONE_1><PHONE_2>+61 8 8313 4099</PHONE_2></ADDRESS></PERSON><PERSON ID="9027" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Neil</FIRST_NAME><LAST_NAME>Johnson</LAST_NAME><EMAIL_1>neiljohnson1964@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Robinson Research Institute</DEPARTMENT><ORGANISATION>University of Adelaide</ORGANISATION><ADDRESS_1>Norwich Centre Ground Floor, 55 King William Road</ADDRESS_1><ADDRESS_2>North Adelaide</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5006</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 8313 1527</PHONE_1><PHONE_2>mobile 0274 360172</PHONE_2></ADDRESS></PERSON><PERSON ID="0A9FF8B382E26AA200DE9984F9827998" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><LAST_NAME>Watson</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>andy.watson@tgh.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Tameside &amp; Glossop Acute Services NHS Trust</DEPARTMENT><ORGANISATION>Tameside General Hospital</ORGANISATION><ADDRESS_1>Fountain Street</ADDRESS_1><CITY>Ashton-Under-Lyne</CITY><ZIP>OL6 9RW</ZIP><REGION>Lancashire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 3316158</PHONE_1><PHONE_2>+44 1332 75148</PHONE_2><FAX_1>+44 161 331 6074</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-05-01 01:12:25 +0100" MODIFIED_BY="Helen Nagels" NOTES="&lt;p&gt;Minor update: 02/01/08&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 01/04/04&lt;/p&gt;&lt;p&gt;Conclusions changed: 01/04/04&lt;/p&gt;" NOTES_MODIFIED="2014-09-25 13:38:10 +1200" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="17" MONTH="6" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="6" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="6" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-04-16 15:46:03 +1200" MODIFIED_BY="Helen E Nagels" NOTES="&lt;p&gt;One new RCT has been included in this update (Al-Fadhli 2006). &lt;br&gt;Data from one study (Letterie 1990) was shifted from the comparison OSCM versus WSCM to OSCM+WSCM versus WSCM after confirmation of the author about the time of testing the fallopian tubes.&lt;br&gt;Intention to treat analysis with imputation of missing data not being pregnant were performed.&lt;br&gt;A random-effects statistical model has been used for the heterogeneous data with the outcome live birth and pregnancy.&lt;br&gt;The statistics have been changed to relative risk (RR) for the outcome of live birth and pregnancy.&lt;/p&gt;" NOTES_MODIFIED="2015-04-16 15:46:03 +1200" NOTES_MODIFIED_BY="Helen E Nagels">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-04-16 15:46:00 +1200" MODIFIED_BY="Helen E Nagels">
<DATE DAY="16" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>Our conclusions have not changed with the addition of one new study.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-04-16 15:46:03 +1200" MODIFIED_BY="Helen E Nagels">
<DATE DAY="16" MONTH="4" YEAR="2015"/>
<DESCRIPTION>
<P>One study added (<LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>); contact details updated; one new comparison added (water-soluble contrast media versus no treatment); risk of bias tables updated; tables of characteristics of included studies updated; review adapted to new format; summary of findings table added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-03-09 08:29:08 +1300" MODIFIED_BY="jane clarke">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-03-09 08:29:08 +1300" MODIFIED_BY="jane clarke">
<DATE DAY="13" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="16" MONTH="4" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-08-26 03:28:21 +1200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-08-26 03:28:21 +1200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-08-26 03:28:21 +1200" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-08-26 03:28:01 +1200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-08-26 03:28:01 +1200" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-04-15 16:56:46 +1200" MODIFIED_BY="Helen E Nagels">
<SUMMARY MODIFIED="2015-04-02 15:42:45 +1300" MODIFIED_BY="Helen E Nagels">
<TITLE>Tubal flushing for subfertility</TITLE>
<SUMMARY_BODY MODIFIED="2015-04-02 15:42:45 +1300" MODIFIED_BY="Helen E Nagels">
<P>
<B>Review question</B>
</P>
<P>Cochrane review authors assessed the evidence to see what effect flushing of the fallopian tubes has on live birth and pregnancy rates in women with subfertility.</P>
<P>
<B>Background</B>
</P>
<P>Blocked fallopian tubes usually means that it is impossible for a woman to conceive as sperm cannot reach the egg in the tube. Establishing whether the tubes are open (patent) is important and requires contrast media (dye) to be pushed through the tubes either at the time of an x-ray (a hysterosalpingogram) or during a laparoscopy (keyhole operation). It has been reported that more women conceive following tubal flushing although it is not clear why this occurs. There has also been debate about which contrast medium should be used (water-soluble or oil-soluble) as this may influence pregnancy rates.</P>
<P>
<B>Study characteristics</B>
</P>
<P>The evidence was current to June 2014. We included randomised controlled trials (RCTs) looking at the effect flushing of the fallopian tubes (with either oil-soluble or water-soluble contrast media) has on live birth and pregnancy rates in women with subfertility. Such women were those who had not been able to conceive after at least six months of unprotected sexual intercourse. We also looked at the rates of adverse events, including miscarriage and ectopic pregnancy (a pregnancy growing outside the womb) after flushing the tubes.</P>
<P>
<B>Key results</B>
</P>
<P>We included 13 RCTs (2914 women). The trials compared oil-soluble and water-soluble media with no intervention and with each other. We found evidence that tubal flushing with oil-soluble media may increase the chances of live birth and ongoing pregnancy, compared to no intervention. Our findings suggest that among subfertile women with a 17% chance of ongoing pregnancy if they have no intervention, the rate will increase to between 29% and 55% if they have tubal flushing with oil-based contrast media. We found no evidence of a difference between water-soluble contrast media and no intervention and the contrast media compared one against the other with respect to live birth and pregnancy, though there were few data for most comparisons. There was no evidence of a difference between any of the groups with respect to adverse events, but such events were poorly reported in most studies.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>The overall quality of the evidence was low or very low for all comparisons. The main limitations were imprecision, risk of bias and inconsistency. There were too few studies to evaluate the risk of publication bias.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-02-25 20:36:20 +1300" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-02-25 20:36:20 +1300" MODIFIED_BY="[Empty name]">
<P>Establishing the patency of the fallopian tubes is a commonly undertaken diagnostic investigation for women with subfertility. This is usually achieved by flushing contrast medium through the tubes and taking radiographs. However, it has been noted that many women conceive in the first three to six months after the tubal flushing, which has raised the possibility that tubal flushing could also be a treatment for infertility. There has been debate about which contrast medium should be used (water-soluble or oil-soluble media) as this may influence pregnancy rates.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-09-25 15:46:25 +1200" MODIFIED_BY="[Empty name]">
<P>To evaluate the effect of flushing fallopian tubes with oil- or water-soluble contrast media on live birth and pregnancy rates in women with subfertility.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-02-25 20:10:14 +1300" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register of trials, MEDLINE, EMBASE, Biological Abstracts, trial registers and reference lists of identified articles. The most recent search was conducted in June 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-02-25 20:13:00 +1300" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing tubal flushing with oil-soluble or water-soluble contrast media, or with no treatment, in women with subfertility.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-25 14:32:14 +1200" MODIFIED_BY="[Empty name]">
<P>Two authors independently selected the trials, assessed risk of bias and extracted data. We contacted study authors for additional information. The overall quality of the evidence was assessed using GRADE methods.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-02-25 20:17:40 +1300" MODIFIED_BY="[Empty name]">
<P>Thirteen trials involving 2914 women were included, of whom 2494 were included in the analysis.</P>
<P>
<B>Oil-soluble contrast media (OSCM) versus no intervention</B>
</P>
<P>The OSCM group had a higher rate of live birth (odds ratio (OR) 3.09, 95% CI 1.39 to 6.91, 1 RCT, 158 women, low quality evidence) and ongoing pregnancy (OR 3.59, 95% CI 2.06 to 6.26, 3 RCTs, 382 women, I<SUP>2</SUP> = 0%, low quality evidence) than women who had no intervention. Our findings suggest that among subfertile women with a 17% chance of an ongoing pregnancy if they have no intervention, the rate will increase to between 29% and 55% if they have tubal flushing with OSCM.</P>
<P>
<B>Water-soluble contrast media (WSCM) versus no intervention</B>
</P>
<P>There was no evidence of a difference between the groups in rates of live birth (OR 1.13, 95% CI 0.67 to 1.91, 1 RCT, 334 women, very low quality evidence) or ongoing pregnancy (OR 1.14, 95% CI 0.71 to 1.84, 1 RCT, 334 women, very low quality evidence).</P>
<P>
<B>OSCM versus WSCM</B>
</P>
<P>Two RCTs reported live birth: one found a higher live birth rate in the oil-soluble group and the other found no evidence of a difference between the groups. These studies were not pooled due to very high heterogeneity (I<SUP>2 </SUP>= 93%). There was no evidence of a difference between the groups in rates of ongoing pregnancy, however there was high heterogeneity (OR 1.44, 95% CI 0.84 to 2.47, 5 RCTs, 1454 women, I<SUP>2 </SUP>= 76%, random-effects model, very low quality evidence).</P>
<P>
<B>OSCM plus WSCM versus WSCM alone</B>
</P>
<P>There was no evidence of a difference between the groups in rates of live birth (OR 1.06, 95% CI 0.64 to 1.77, 1 RCT, 393 women, very low quality evidence) or ongoing pregnancy (OR 1.23, 95% CI 0.87 to 1.72, 4 RCTs, 633 women, I<SUP>2 </SUP>= 0%, low quality evidence).</P>
<P>There was no evidence of a difference between any of the interventions in rates of adverse events, but such events were poorly reported in most studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-02-25 20:18:31 +1300" MODIFIED_BY="[Empty name]">
<P>The evidence suggests that tubal flushing with oil-soluble contrast media may increase the chance of pregnancy and live birth compared to no intervention. Findings for other comparisons were inconclusive due to inconsistency and lack of statistical power. There was insufficient evidence on adverse events to reach firm conclusions. Further robust randomised controlled trials are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-03-10 13:49:52 +1300" MODIFIED_BY="Helen E Nagels">
<BACKGROUND MODIFIED="2015-02-26 15:31:21 +1300" MODIFIED_BY="Helen E Nagels">
<CONDITION MODIFIED="2015-02-25 20:40:24 +1300" MODIFIED_BY="[Empty name]">
<P>Establishing the patency of the fallopian tubes is a commonly undertaken diagnostic investigation for women with subfertility. This is usually achieved by flushing contrast medium through the tubes and taking radiographs. However, it has been noted that many women conceive in the first three to six months after the tubal flushing, which has raised the possibility that tubal flushing could also be a treatment for subfertility. There has been debate about which contrast medium should be used (water-soluble or oil-soluble media) as this may influence pregnancy rates.</P>
<P>A doubling of conception rate after a hysterosalpingogram (HSG) with oily media was reported when compared to those women who had no procedure (<LINK REF="REF-Weir-1951" TYPE="REFERENCE">Weir 1951</LINK>). Many reports on the therapeutic aspect of oil-soluble contrast media have been published since the 1960s. However, many of these did not have satisfactory control groups. Various agents have been used primarily for diagnostic purposes in assessing tubal patency, such as methylene blue water-soluble dye in conjunction with laparoscopy and the water-soluble contrast media (WSCM) and oil-soluble contrast media (OSCM) used for an HSG. Other agents have been used in the past primarily for therapeutic purposes, such as carbon dioxide tubal insufflation and oil injection, although these do not form part of current routine practice in most centres (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-02-26 15:31:21 +1300" MODIFIED_BY="Helen E Nagels">
<P>Traditionally HSGs were performed with OSCM. Their use was gradually replaced by WSCM for a number of reasons, (i) WSCM permits better imaging of the tubal mucosal folds and ampullary rugae (internal architecture of the fallopian tubes) than OSCM (<LINK REF="REF-Soules-1982" TYPE="REFERENCE">Soules 1982</LINK>); (ii) OSCM have a high viscosity, which results in slow filling of the fallopian tubes often necessitating an inconveniently late film after 24 hours; (iii) OSCM reabsorption is slow, leading to prolonged persistence of OSCM within the pelvic cavity; (iv) if there is accumulation of OSCM within a blocked fallopian tube a chronic inflammatory reaction, called a lipo-granuloma, may occur; this has not been reported in women with patent fallopian tubes and is not known to have long-term consequences (<LINK REF="STD-Acton-1988" TYPE="STUDY">Acton 1988</LINK>); (v) the potential consequences of intravasation of OSCM into the pelvic blood vessels and lymphatics are allergic reactions or anaphylaxis (<LINK REF="REF-Lindequist-1991" TYPE="REFERENCE">Lindequist 1991</LINK>); and (vi) WSCM are generally cheaper than OSCM.</P>
<P>On the other hand, irrespective of subsequent pregnancy rates, OSCM offer some advantages over WSCM, (i) the slow filling of the fallopian tubes owing to the higher viscosity of OSCM can necessitate a 'late' film but some authorities regard the 24-hour film as an advantage because of the additional information this gives, mainly in the evaluation of adhesions after slow peritoneal spillage (<LINK REF="REF-Bateman-1987" TYPE="REFERENCE">Bateman 1987</LINK>); and (ii) less pain has been reported with OSCM than with WSCM, probably because of less chemical irritation of the peritoneum (<LINK REF="REF-Soules-1982" TYPE="REFERENCE">Soules 1982</LINK>).<BR/>
</P>
<P>One of the earlier descriptions of a possible beneficial therapeutic effect of OSCM came from a radiologist (<LINK REF="STD-Gillespie-1965" TYPE="STUDY">Gillespie 1965</LINK>). Gillespie had changed practice from OSCM to WSCM for safety reasons. A decreased pregnancy rate from 41% to 27% over the following 12 months prompted a change back to the use of oily media, and the pregnancy rate rose again to 44%. Other non-randomised controlled studies (<LINK REF="STD-Acton-1988" TYPE="STUDY">Acton 1988</LINK>; <LINK REF="STD-Barwin-1971" TYPE="STUDY">Barwin 1971</LINK>; <LINK REF="STD-DeCherney-1980" TYPE="STUDY">DeCherney 1980</LINK>; <LINK REF="STD-Mackey-1971" TYPE="STUDY">Mackey 1971</LINK>; <LINK REF="STD-Yaegashi-1987" TYPE="STUDY">Yaegashi 1987</LINK>) supported the hypothesis of the fertility-enhancing effect of OSCM.</P>
<P>With the advent of fluoroscopy, screening severe adverse reactions following the use of oily media in radiology have been reduced (<LINK REF="REF-Lindequist-1991" TYPE="REFERENCE">Lindequist 1991</LINK>). The safety of HSGs with OSCM in this context has been confirmed (<LINK REF="REF-Nunley-1987" TYPE="REFERENCE">Nunley 1987</LINK>).</P>
<P>Despite data suggesting a fertility-enhancing effect of tubal flushing, particularly with OSCM, this does not form part of routine current practice. There has been a reluctance to embrace this as a standard treatment, possibly relating to the following.<BR/>(a) Prior beliefs amongst clinicians which have not, to date, been sufficiently swayed by available data, the criticisms have included:<BR/>(i) that data on sexual frequency were not available for the 'flushing' versus 'no treatment' trials prior to the RCT by <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>, hence the notion that the increased pregnancy rate might be due simply to an increased sexual frequency in the group who received treatment. However, <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK> found no evidence that a change in sexual behaviour in the OSCM treatment group compared to the no treatment group led to an increased pregnancy rate;<BR/>(ii) much of the data were from trials where the interventions were performed as diagnostic tests rather than as therapeutic interventions.<BR/>(b) A trend towards in vitro fertilisation (IVF) as the panacea for all causes of subfertility.</P>
<P>The first systematic review in this field was published in 1994 (<LINK REF="REF-Watson-1994" TYPE="REFERENCE">Watson 1994</LINK>). The original Cochrane Review (<LINK REF="REF-Vandekerckhove-1996" TYPE="REFERENCE">Vandekerckhove 1996</LINK>), first published in 1996, was an expansion and update of that review. There have since been four further updates, in 2002 (<LINK REF="REF-Johnson-2002" TYPE="REFERENCE">Johnson 2002</LINK>), 2005 (<LINK REF="REF-Johnson-2005-_x0028_a_x0029_" TYPE="REFERENCE">Johnson 2005 (a)</LINK>, <LINK REF="REF-Johnson-2005-_x0028_c_x0029_" TYPE="REFERENCE">Johnson 2005 (c)</LINK>), 2007 (<LINK REF="REF-Johnson-2007" TYPE="REFERENCE">Johnson 2007</LINK>) and this current update.
</P>
</INTERVENTION>
<THEORY MODIFIED="2015-02-25 21:00:35 +1300" MODIFIED_BY="[Empty name]">
<P>There are a number of explanations behind the theory of flushing of the fallopian tubes. These are detailed in the discussion section and include the following.</P>
<P>(i) Flushing out debris from the fallopian tubes, therefore unblocking undamaged tubes. Such debris may not necessarily block the fallopian tube but may hinder conception or embryo transport along the fallopian tube. The observation that lipiodol tubal flushing is effective for women with confirmed tubal patency (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>) would support this. Furthermore, there is increasing evidence that some cases of 'blocked' fallopian tubes may have been due simply to tubal plugs, dislodged by OSCM, and thus such participants could be classified on the basis of OSCM HSG findings as having unexplained subfertility.</P>
<P>Histological examination of resected 'obstructed' tubal segments often fails to confirm luminal occlusion (<LINK REF="REF-Grant-1971" TYPE="REFERENCE">Grant 1971</LINK>) but amorphous matter has been found within tubal sections (<LINK REF="REF-Sulak-1987" TYPE="REFERENCE">Sulak 1987</LINK>) and its presence confirmed at falloposcopy (<LINK REF="REF-Kerin-1991" TYPE="REFERENCE">Kerin 1991</LINK>). Histology of this tissue, obtained by hydrotubating the tube at falloposcopy, has revealed casts of the tube comprised of aggregates of histiocytic-like cells from the mucosal stroma.</P>
<P>Observational studies (<LINK REF="REF-Capitanio-1991" TYPE="REFERENCE">Capitanio 1991</LINK>; <LINK REF="REF-Novy-1988" TYPE="REFERENCE">Novy 1988</LINK>; <LINK REF="REF-Thurmond-1990" TYPE="REFERENCE">Thurmond 1990</LINK>) have reported a high tubal patency and pregnancy rate after selective transcervical fallopian tube catheterisation under fluoroscopic or hysteroscopic control in patients with previously diagnosed proximal tubal obstruction on HSG with a WSCM or dye laparoscopy. This might be attributable to the 'flushing out' of isthmic plugs.</P>
<P>
<LINK REF="REF-Thurmond-1990" TYPE="REFERENCE">Thurmond 1990</LINK> achieved tubal patency on at least one side in 86 of 100 consecutive women with subfertility and proximal tubal obstruction, and found that 9 of 20 women who had bilateral cornual blockage and were waiting for tubal surgery or IVF conceived after using the above technique with the majority doing so in the first four cycles after selective tubal catheterisation.</P>
<P>(ii) Modulation of peritoneal macrophages (<LINK REF="REF-Johnson-1992" TYPE="REFERENCE">Johnson 1992</LINK>). OSCM have been shown to alter interleukin and prostaglandin production by peritoneal macrophages (<LINK REF="REF-Sawatari-1993" TYPE="REFERENCE">Sawatari 1993</LINK>) and to modulate peritoneal macrophage activity amongst rats during phagocytosis of sperm (<LINK REF="REF-Mikulska-1994" TYPE="REFERENCE">Mikulska 1994</LINK>).</P>
<P>(iii) Increasing endometrial receptivity by altering endometrial leukocyte populations. The pregnancy-enhancing effect might simply lie at the level of the endometrium. For most couples unsuccessful with IVF treatment, the outcome hinges on failed implantation. It stands to reason that a treatment which substantially increases the likelihood of conception will have some effect on endometrial receptivity.</P>
<P>It is possible that endometrial leukocyte populations may be altered and there is increasing evidence that uterine natural killer cells play an important role in the successful development of early pregnancy (<LINK REF="REF-Fukui-1999" TYPE="REFERENCE">Fukui 1999</LINK>). We now have evidence that uterine dendritic cell populations are influenced by flushing the murine genital tract with the OSCM lipiodol (unpublished observations).</P>
<P>(iv) Other theories with less supporting evidence include 'straightening' of tortuous fallopian tubes, disruption of peritubular adhesions, stimulation of tubal ciliary action, improving cervical mucus, and an iodine-induced bacteriostatic action on mucous membranes.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-09-25 16:07:19 +1200" MODIFIED_BY="[Empty name]">
<P>Tubal flushing is a low-cost minimally invasive investigation which is routinely undertaken during initial assessment of infertile couples. We aimed to establish whether tubal flushing is safe and effective for improving fertility outcomes in subfertile women.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-09-25 16:07:39 +1200" MODIFIED_BY="[Empty name]">
<P>To evaluate the effect of flushing fallopian tubes with oil- or water-soluble contrast media on live birth and pregnancy rates in women with subfertility.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-02-25 23:08:43 +1300" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-02-25 21:06:28 +1300" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-02-25 21:02:00 +1300" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) were included. Non-randomised studies and quasi-randomised studies were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-02-25 21:02:07 +1300" MODIFIED_BY="[Empty name]">
<P>Women with subfertility, defined as inability to achieve pregnancy after at least six months of regular unprotected intercourse.<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-02-25 21:02:37 +1300" MODIFIED_BY="[Empty name]">
<P>Tubal flushing by means of hysterosalpingography (HSG)<BR/>Tubal flushing at the time of laparoscopy<BR/>Tubal flushing at the time of HyCoSy (hysterosalpingo contrast sonography)</P>
<P>Control groups could receive placebo, no treatment or an alternative type of tubal flushing.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-02-25 21:06:28 +1300" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-02-25 21:04:46 +1300" MODIFIED_BY="[Empty name]">
<OL>
<LI>Live birth per woman</LI>
<LI>Ongoing pregnancy per woman (preferably defined as an ultrasound-confirmed gestational sac at 12 weeks)</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-02-25 21:06:28 +1300" MODIFIED_BY="[Empty name]">
<P>3. Miscarriage per pregnancy</P>
<P>4. Ectopic pregnancy per pregnancy</P>
<P>5. Procedural pain, immediate and delayed</P>
<P>6. Short-term adverse events (intravasation, infection, haemorrhage)</P>
<P>7. Image quality, of the uterine cavity and tubal ampulla</P>
<P>8. Long-term complications</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-02-25 22:54:32 +1300" MODIFIED_BY="[Empty name]">
<P>We searched for all published and unpublished RCTs of tubal flushing for women with subfertility, without language restriction and in consultation with the Menstrual Disorders and Subfertility Group (MDSG) Trials Search Co-ordinator. The most recent search was conducted in June 2014.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-02-25 22:53:08 +1300" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases, trial registers and websites:</P>
<UL>
<LI>Menstrual Disorders and Subfertility Group (MDSG) Specialised Register of controlled trials</LI>
<LI>MEDLINE</LI>
<LI>EMBASE</LI>
<LI>CENTRAL</LI>
<LI>PsycINFO</LI>
<LI>Biological Abstracts</LI>
</UL>
<P>The MEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomised trials, which appears in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (Version 5.0.2, chapter 6, 6.4.11). The EMBASE and PsycINFO searches were combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<A HREF="http://www.sign.ac.uk/methodology/filters.html#random">http://www.sign.ac.uk/methodology/filters.html#random</A>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Other electronic sources of trials</HEADING>
<P>Trials registers were searched for ongoing and registered trials:</P>
<UL>
<LI>National Research Register (NRR) (www2.le.ac.uk/library/find/databases/n/nationalresearchregister);</LI>
<LI>Current Controlled Trials (http://www.controlled-trials.com);</LI>
<LI>NHS Centre for Reviews and Dissemination (www.crd.york.ac.uk/CRDWeb/);</LI>
<LI>US National Institutes of Health (NHI) Clinical Trials Register (<A HREF="http://clinicaltrials.gov/ct2/home">www.clinicaltrials.gov</A>).</LI>
</UL>
<P>We searched for any trials with the following keywords:<BR/>1. hysterosalpingogram, HSG or salpingogram;<BR/>2. lipiodol or ethiodol;<BR/>3. water-soluble contrast media, WSCM, oil-soluble contrast media or OSCM;<BR/>4. tubal flushing.<BR/>
</P>
<P>The search strategies can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-02-25 22:54:32 +1300" MODIFIED_BY="[Empty name]">
<P>We checked the citation lists of included trials, eligible studies and relevant review articles. We contacted the first or corresponding authors of trials eligible for inclusion to ascertain if they were aware of any ongoing or unpublished trials.</P>
<P>We searched abstract booklets from scientific meetings, including the European Society of Human Reproduction and Embryology, the World Congress of IVF and Reproductive Genetics, the British Fertility Society, the Fertility Society of Australia and the British Congress of Obstetrics and Gynaecology.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-02-25 23:08:43 +1300" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-02-25 22:54:53 +1300" MODIFIED_BY="[Empty name]">
<P>After an initial screen of titles and abstracts retrieved by the search, we retrieved the full texts of all potentially eligible studies. Two review authors (LM and AH) independently selected the trials for inclusion. Differences of opinion were resolved by consensus after consultation with the other review author (AJW).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-02-25 22:55:47 +1300" MODIFIED_BY="[Empty name]">
<P>Two of the review authors (LM and AH) independently extracted data, and differences of opinion were resolved by consensus. We sought additional information on trial methodology or actual original trial data from the corresponding authors of trials which appeared to meet the eligibility criteria if aspects of methodology were unclear, or if data were in a form unsuitable for meta-analysis.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-02-25 22:56:30 +1300" MODIFIED_BY="[Empty name]">
<P>Two review authors (LM and AH) independently assessed the included studies using the Cochrane risk of bias assessment tool. Disagreements were resolved by discussion. The conclusions were presented in the 'Risk of bias' table (and for summary see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and incorporated into the interpretation of review findings by means of sensitivity analyses.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-02-25 22:57:14 +1300" MODIFIED_BY="[Empty name]">
<P>For dichotomous data the numbers of events in the control and intervention groups of each study were used to calculate Mantel-Haenszel odds ratios (ORs) and 95% confidence intervals (95% CI).</P>
<P>For continuous data (for example procedural pain), mean differences (MDs) and 95% CIs were calculated.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-09-25 14:49:56 +1200" MODIFIED_BY="[Empty name]">
<P>The primary analysis was per woman randomised. Miscarriage and ectopic pregnancy were analysed per pregnancy.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-02-25 22:58:05 +1300" MODIFIED_BY="[Empty name]">
<P>The data were analysed on an intention-to-treat basis as far as possible and attempts were made to obtain missing data from the original investigators. Where these were unobtainable, imputation of individual values was undertaken for the primary outcomes only. Live births were assumed not to have occurred in participants with unreported outcomes.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-02-25 23:00:52 +1300" MODIFIED_BY="[Empty name]">
<P>Statistical heterogeneity between the results of different studies was examined by checking the results of Chi<SUP>2</SUP> tests and the I<SUP>2</SUP> percentage value. If the I<SUP>2</SUP> was &gt; 50% and Chi<SUP>2</SUP> P value &lt; 0.05, indicating substantial heterogeneity, this was addressed through sensitivity analysis. If I<SUP>2 </SUP>was &gt; 80%, then the data were not pooled in a meta-analysis.</P>
<P>If statistical heterogeneity was present, although the results were pooled, reasons for the heterogeneity were sought and the meta-analysis results interpreted cautiously.</P>
<P>As part of the heterogeneity assessment we carried out a set of a priori defined subgroup analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-02-25 23:01:26 +1300" MODIFIED_BY="[Empty name]">
<P>In view of the difficulty in detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies<I>.</I> If there were 10 or more studies in an analysis, we planned to use a funnel plot to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-02-25 23:04:59 +1300" MODIFIED_BY="[Empty name]">
<P>If the studies were sufficiently similar, we combined the data using a fixed-effect model in the following comparisons.<BR/>
</P>
<UL>
<LI>Tubal flushing with OSCM versus no treatment.</LI>
<LI>Tubal flushing with WSCM versus no treatment.</LI>
<LI>Tubal flushing with OSCM versus WSCM.</LI>
<LI>Tubal flushing with OSCM and WSCM versus WSCM alone.</LI>
</UL>
<P>An increase in the odds of a particular outcome (which may be beneficial, for example in the case of live birth; or detrimental, for example in the case of a complication) was displayed graphically in the meta-analyses to the right of the centre-line and a decrease in the odds of an outcome was displayed graphically to the left of the centre line.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-02-25 23:07:07 +1300" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was performed to determine whether findings differed in studies performed mainly for diagnostic reasons as opposed to studies performed mainly for therapeutic reasons.</P>
<P>If we detected significant heterogeneity (defined as P &lt; 0.05 in the Chi<SUP>2</SUP> heterogeneity test), we explored possible explanations in sensitivity analyses. We used a random-effects model if significant heterogeneity was present.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-02-25 23:08:43 +1300" MODIFIED_BY="[Empty name]">
<P>A priori, we planned the following sensitivity analyses for the primary outcomes:</P>
<P>a) restricting the analysis to studies at low risk of bias;</P>
<P>b) using alternative imputation methods;</P>
<P>c) based on the source of data (whether it was a diagnostic or a therapeutic study);</P>
<P>d) using risk ratios instead of odds ratios;</P>
<P>e) using a random-effects model instead of a fixed-effect model.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-03-03 12:28:30 +1300" MODIFIED_BY="Helen E Nagels">
<STUDY_DESCRIPTION MODIFIED="2015-02-25 23:25:16 +1300" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-02-25 23:11:43 +1300" MODIFIED_BY="[Empty name]">
<P>The 2014 search retrieved 207 discrete articles. Eleven studies were potentially eligible and were retrieved in full text for further consideration. One study (<LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>) met our inclusion criteria and 10 were excluded. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Twelve studies were included in previous versions of the review, so the updated version included 13 studies (2582 analysed participants). See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>See <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for details of the screening and selection process.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-02-25 23:23:50 +1300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Types of studies</HEADING>
<P>The 13 included studies were all parallel group RCTs:</P>
<UL>
<LI>six trials were conducted primarily for therapeutic reasons (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>; <LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>);</LI>
<LI>seven trials were conducted primarily for diagnostic reasons (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of interventions</HEADING>
<UL>
<LI>Three trials including 382 analysed participants assessed tubal flushing with OSCM versus no treatment (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>).</LI>
<LI>One trial assessed tubal flushing with WSCM versus no treatment (<LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>).</LI>
<LI>Six trials with 1483 participants assessed flushing with contrast which included OSCM versus flushing with WSCM alone (OSCM versus WSCM) (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>; <LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>).</LI>
<LI>Three trials (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>) compared OSCM + WSCM versus WSCM tubal flushing. <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK> also included an arm receiving tubal flushing with both WSCM and OSCM. These four trials included a total of 633 participants for this comparison.</LI>
</UL>
<P>The included studies and their methodological details are summarised in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of participants</HEADING>
<P>Women or couples with unexplained infertility were considered eligible for inclusion. Thirteen studies with a total of 2582 analysed participants were included in this review. The number of participants in each study ranged from 34 (<LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>) to 666 (<LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>).</P>
<P>The duration of infertility was at least six months in all but three trials where duration of infertility was not specified (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>).</P>
<P>The mean age or age range was not stated in two trials (<LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>) and the exclusion criteria were not stated in four trial comparisons (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>).</P>
<P>The remaining trials based their exclusion criteria on iodine allergy (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>), bilateral tubal blockage (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>), previous infertility surgery (<LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>), male factor infertility, suspected anovulation (<LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>), technical difficulties with the HSG (<LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>) and causes of infertility other than unexplained (<LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Type of outcome measures</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Primary outcomes</I>
</HEADING>
<P>Our primary outcomes were live birth and ongoing pregnancy. Four studies reported live birth (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>). All 13 studies reported ongoing pregnancy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Secondary outcomes</I>
</HEADING>
<P>Four studies reported miscarriage (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>; <LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>).</P>
<P>Three studies reported ectopic pregnancy (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>).</P>
<P>Two reported procedural pain (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>).</P>
<P>Two reported short-term adverse events (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>).</P>
<P>One reported image quality (<LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>).</P>
<P>None reported long-term complications.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-02-25 23:25:16 +1300" MODIFIED_BY="[Empty name]">
<P>Ten studies were excluded from the review: one was not truly randomised with the use of alternate assignment (<LINK REF="STD-Schwabe-1983" TYPE="STUDY">Schwabe 1983</LINK>), five were non-randomised comparative studies of HSG with OSCM versus WSCM (<LINK REF="STD-Acton-1988" TYPE="STUDY">Acton 1988</LINK>; <LINK REF="STD-Barwin-1971" TYPE="STUDY">Barwin 1971</LINK>; <LINK REF="STD-DeCherney-1980" TYPE="STUDY">DeCherney 1980</LINK>; <LINK REF="STD-Gillespie-1965" TYPE="STUDY">Gillespie 1965</LINK>; <LINK REF="STD-Yaegashi-1987" TYPE="STUDY">Yaegashi 1987</LINK>), one was a three-way non-randomised comparative study of HSG with OSCM versus WSCM versus no treatment (<LINK REF="STD-Mackey-1971" TYPE="STUDY">Mackey 1971</LINK>), and one did not report pregnancy outcomes (<LINK REF="STD-Wolf-1989" TYPE="STUDY">Wolf 1989</LINK>). Another was a recent observational study of pregnancy rates in women undergoing HSG with OSCM (<LINK REF="STD-Court-2014" TYPE="STUDY">Court 2014</LINK>). See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-02-25 23:37:12 +1300" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; 
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.<BR/>
</P>
<ALLOCATION MODIFIED="2015-02-25 23:28:58 +1300" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Sequence generation</HEADING>
<P>Seven trials were rated as at low risk of bias in this domain as they used computer-generated lists or random number tables (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>; <LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>; <LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>). The method of sequence generation was not adequately described in seven studies, which were rated as at unclear risk of bias (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment</HEADING>
<P>Adequate concealment of assigned treatment prior to allocation was reported in three trials (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002)</LINK> which were rated as at low risk of bias in this domain. Ten studies did not clearly report an adequate method of allocation concealment and were rated as at unclear risk (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>; <LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>; <LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2015-02-25 23:29:53 +1300" MODIFIED_BY="[Empty name]">
<P>Only one trial (<LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>) was double-blinded, though it was not specifically stated that outcome assessment was blinded. None of the other trials stated that blinding was used, although participant blinding would have been possible in trials where different contrast media were compared. All trials could have been single-blinded for the investigators assessing outcomes. Our primary outcome (live birth and ongoing pregnancy) may not be unduly prone to bias related to lack of blinding, but there may be scope for bias related to more thorough follow up by investigators to find outcomes in couples not attending follow-up clinics. All studies were rated as at unclear risk of bias in this domain.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-02-25 23:36:01 +1300" MODIFIED_BY="[Empty name]">
<P>Randomisation was undertaken some time in advance of the tubal flushing procedure itself (at referral and at scheduling) in four trials (<LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>) and subsequently a number of participants were withdrawn before they underwent the HSG because they had conceived, changed their mind about undergoing the procedure or participating in the trial, or were subsequently found not to fulfil the criteria for the trial. Randomisation immediately before the procedure was more appropriate.</P>
<P>Withdrawals and losses to follow up after HSG varied from 0% (<LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>), 1% (<LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>), 3% (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>), 5% (<LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>), 9% (<LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>), 11% (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>), 19% (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>), 21% (<LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>), 22% (<LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>), 28% (<LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>) and 37% (<LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>) of participants who underwent the procedure; this was unclear for one trial (<LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>). The highest withdrawal rate of 37% (<LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>) was due to the fact that women underwent the HSG (or not) before any results of their other investigations were known, and only women with proof of ovulation in all four cycles of follow up were retained in the analysis. Incompleteness or loss to follow up accounted for approximately one half of the withdrawals in the other trials.</P>
<P>Other than in the trials where all randomised participants were analysed, it was impossible to recalculate the treatment effect based on the originally randomised groups (using the intention-to-treat principle). It was not obvious that the intention-to-treat principle was the best approach for analysis given the poor design (randomisation before eligibility established) of some of the trials. However, it is generally recommended to minimize bias in the design, conduct and analysis of RCTs of effectiveness. Only two trials (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>;) performed an intention-to-treat analysis. Only one trial (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>) specified outcome details for participants withdrawn from each randomised group. Recalculation of the OR including these participants had little effect on the conclusions of this trial (OR 1.31, 95% CI 0.51 to 3.04 for all participants versus OR 1.31, 95% CI 0.56 to 3.09 after exclusion).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-02-25 23:37:12 +1300" MODIFIED_BY="[Empty name]">
<P>All studies reported live birth or pregnancy, or both. However, five studies failed to report any adverse events (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>; <LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>) and one did not clearly report how pregnancy was ascertained (<LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>). These studies were rated as at unclear risk of selctive reporting, while others were rated as at low risk.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-10-29 09:57:23 +1300" MODIFIED_BY="Helen E Nagels">
<P>We found no potential sources of within-study bias in the included studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-03-03 12:28:30 +1300" MODIFIED_BY="Helen E Nagels">
<SUBSECTION>
<HEADING LEVEL="3">(1) Tubal flushing with OSCM versus no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Live birth</HEADING>
<P>Only one study (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>) making this comparison reported live birth. Tubal flushing with OSCM was associated with a significant increase in the odds of ongoing pregnancy (OR 3.09, 95% CI 1.39 to 6.91, 1 RCT, 158 women). See <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Ongoing pregnancy</HEADING>
<P>Three studies (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>; <LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>) making this comparison reported ongoing pregnancy (OR 3.59, 95% CI 2.06 to 6.26, 3 RCTs, 382 women, I<SUP>2 </SUP>= 0%). See <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>Findings were similar in trials either with a diagnostic or with a therapeutic focus.</P>
<UL>
<LI>In trials where the intervention was intended primarily as a diagnostic test (<LINK REF="STD-Ogata-1993" TYPE="STUDY">Ogata 1993</LINK>): pregnancy OR 3.48 (95% CI 1.42 to 8.52).</LI>
<LI>In trials where the intervention was intended primarily as a therapy (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>): pregnancy OR 3.67 (95% CI 1.81 to 7.44).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analyses</HEADING>
<P>None of the planned sensitivity analyses substantially altered the main findings.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Miscarriage per pregnancy</HEADING>
<P>Only one study (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>) reported miscarriage rate per pregnancy. There was no evidence of a difference between the groups (OR 1.00, 95% CI 0.16 to 6.25, 1 RCT, 42 pregnancies). See <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.4 Ectopic pregnancy</HEADING>
<P>Only one study (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>) reported ectopic pregnancy. There was no evidence of a difference between the groups (OR 1.58, 95% CI 0.06 to 41.34, 1 RCT, 42 pregnancies). See <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.5 Procedural pain, immediate and delayed</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.6 Short-term adverse events (intravasation, infection, haemorrhage)</HEADING>
<P>One study (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>) reported 2 cases of asymptomatic intravasation without sequelae in the OSCM group (n = 73) and no other adverse events. <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK> also stated there were no adverse events. The remaining studies in this group did not report on these outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.7 Image quality, of the uterine cavity and tubal ampulla</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.8 Long-term complications</HEADING>
<P>Two studies in this group (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Nugent-2002" TYPE="STUDY">Nugent 2002</LINK>) stated that there were no long-term complications. This outcome was not reported in the remaining studies.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(2) Tubal flushing with WSCM versus no treatment</HEADING>
<P>Only one study made this comparison (<LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>): women undergoing hysterosalpingo contrast sonography (HyCoSy) as a part of subfertility investigation were included.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Live birth</HEADING>
<P>There was no evidence of a difference between the groups in live birth rates (OR 1.13, 95% CI 0.67 to 1.91, 1 RCT, 334 women). See <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Ongoing pregnancy</HEADING>
<P>There was no evidence of a difference between the groups in ongoing pregnancy rates (OR 1.14, 95% CI 0.71 to 1.84, 1 RCT, 334 women). See <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analyses</HEADING>
<P>Use of risk ratios did not affect the findings for this comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Miscarriage</HEADING>
<P>There was no evidence of a difference between the groups in miscarriage rates (OR 1.12, 95% CI 0.42 to 2.96, 1 RCT, 40 pregnancies). See <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Ectopic pregnancy</HEADING>
<P>There was no evidence of a difference between the groups in ectopic pregnancy rates (OR 0.90, 95% CI 0.05 to 14.76, 1 RCT, 40 pregnancies). See <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Procedural pain, immediate and delayed</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Short-term adverse events (intravasation, infection, haemorrhage)</HEADING>
<P>There was one case of pelvic infection (n = 149) requiring treatment with intravenous antibiotics.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Image quality, of the uterine cavity and tubal ampulla</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.8 Long-term complications</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(3) Tubal flushing with OSCM versus WSCM</HEADING>
<P>Five studies made this comparison (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>; <LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Live birth</HEADING>
<P>Two studies reported this outcome (<LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>). They were not pooled due to extreme statistical heterogeneity (I<SUP>2 </SUP>= 94%).</P>
<P>One of these studies (<LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>) reported a higher live birth rate in the OSCM group (OR 3.45, 95% CI 1.97 to 6.03, 1 RCT, 398 women). The other found no difference between the groups (OR 0.92, 95% CI 0.60 to 1.40, 1 RCT, 533 women, random-effects model). No obvious explanation was found for this inconsistency in findings, although age differences at baseline in one of the studies (<LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>) may have favoured WSCM to some degree. See <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>.</P>
<P>
<B>3.2 Ongoing pregnancy </B>
</P>
<P>All five studies reported ongoing pregnancy. There was no evidence of a difference between the groups (OR 1.44, 95% CI 0.84 to 2.47, 5 RCTs, 1454 women, I<SUP>2 </SUP>= 76%, random-effects model). The high heterogeneity was mainly due the effects of one study (<LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>) that found a benefit for WSCM. Heterogeneity reduced to I<SUP>2 </SUP>= 24% when this study was excluded from the analysis, and the overall finding of no difference between the groups did not change. See <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>. No obvious reason for the heterogeneity was identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>All studies making this comparison were conducted primarily for diagnostic reasons.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analyses</HEADING>
<P>None of the sensitivity analyses affected the findings for this comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Miscarriage</HEADING>
<P>One study (<LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>) reported miscarriage. There was no evidence of a difference between the groups (OR 0.82 95% CI 0.40, 1.64, 1 RCT, 158 pregnancies). See <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 Ectopic pregnancy</HEADING>
<P>One study (<LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>) reported ectopic pregnancy. There was no evidence of a difference between the groups (OR 0.56, 95% CI 0.10 to 3.12, 1 RCT, 158 pregnancies). See <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.5 Procedural pain, immediate and delayed</HEADING>
<P>One study (<LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>) reported the incidence of any postprocedural pain. Pain was less frequently reported in the OSCM group (OR 0.13, 95% CI 0.08 to 0.22, 1 RCT, 417 women). See <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>.</P>
<P>A second study (<LINK REF="STD-Alper-1986" TYPE="STUDY">Alper 1986</LINK>) measured procedural pain 15 minutes after the intervention and found no difference between the groups on a scale of 0 to 5 (MD -0.30, 95% CI -0.78 to 0.18, 1 RCT, 106 women). See <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.6 Short-term adverse events (intravasation, infection, haemorrhage)</HEADING>
<P>The odds of the complication intravasation were higher with OSCM (OR 5.05, 95% CI 2.27 to 11.22, 3 RCTs, 768 women, I<SUP>2 </SUP>= 0%) (<LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>).</P>
<P>There was no evidence of a difference between the groups in the odds of infection (OR 0.21, 95% CI 0.03 to 1.62, 2 RCTs, 662 women) or post-procedure bleeding (OR 0.65, 95% CI 0.40 to 1.06, 2 RCTS, 662 women, I<SUP>2 </SUP>= 0%) (<LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>).</P>
<P>No serious complications were reported in these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.7 Image quality, of the uterine cavity and tubal ampulla</HEADING>
<P>The odds of obtaining a satisfactory image were lower for OSCM than for WSCM, for both the uterine cavity (Peto OR 0.18, 95% CI 0.12 to 0.26) and the tubal ampulla (Peto OR 0.05, 95% CI 0.04 to 0.07) (<LINK REF="STD-De-Boer-1988" TYPE="STUDY">De Boer 1988</LINK>; <LINK REF="STD-Lindequist-1994" TYPE="STUDY">Lindequist 1994</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.8 Long-term complications</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">(4) Tubal flushing with OSCM + WSCM versus WSCM</HEADING>
<P>Four studies made this comparison (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Live birth</HEADING>
<P>One study reported live birth (<LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>). There was no evidence of a difference between the groups (OR 1.06, 95% CI 0.64 to 1.77, 1 RCT, 393 women). See <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 Ongoing pregnancy</HEADING>
<P>Four studies reported ongoing pregnancy (<LINK REF="STD-Al_x002d_Fadhli-2006" TYPE="STUDY">Al-Fadhli 2006</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>; <LINK REF="STD-Steiner-2003" TYPE="STUDY">Steiner 2003</LINK>; <LINK REF="STD-Yang-1989" TYPE="STUDY">Yang 1989</LINK>). There was no evidence of a difference between the groups (OR 1.23, 95% CI 0.87 to 1.72, 4 RCTs, 633 women, I<SUP>2 </SUP>= 0%). See <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>Findings did not differ substantially when the studies were subgrouped into therapeutic and diagnostic studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sensitivity analyses</HEADING>
<P>None of the sensitivity analyses affected the findings for this comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.3 Miscarriage</HEADING>
<P>There was no evidence of a difference between the groups in miscarriage rates (OR 1.14, 95% CI 0.53 to 2.48, 1 RCT, 393 women) (<LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4 Ectopic pregnancy</HEADING>
<P>There were no significant differences in ectopic pregnancy (OR 0.48, 95% CI 0.05 to 4.38, 2 RCTs, 422 women) (<LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.5 Procedural pain, immediate and delayed</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.6 Short-term adverse events (intravasation, infection, haemorrhage)</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.7 Image quality, of the uterine cavity and tubal ampulla</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.8 Long-term complications</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>A subgroup analysis for whether the intervention was performed by HSG or laparoscopy did not significantly alter the outcome for either pregnancy rate after tubal flushing at laparoscopy (Peto OR 1.93, 95% CI 0.85 to 4.38) or hysterosalpingography (Peto OR 1.18, 95% CI 0.82 to 1.70).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-03-10 13:49:52 +1300" MODIFIED_BY="Helen E Nagels">
<P> </P>
<SUMMARY_OF_RESULTS MODIFIED="2015-02-26 00:14:28 +1300" MODIFIED_BY="[Empty name]">
<P>The results of this systematic review give some evidence that tubal flushing with OSCM increases the pregnancy rate compared no treatment. Our findings suggest that among women with a 17% chance of ongoing pregnancy if they have no intervention, the rate will increase to 29% to 35% if they have tubal flushing with OSCM. Findings for other comparisons were inconclusive due to inconsistency and lack of statistical power.</P>
<P>There was no evidence of a difference between any of the groups with respect to adverse events, but such events were poorly reported in most studies.</P>
<P>The success rates of fertility treatments are best assessed in terms of live birth, and only 4 of the 13 studies included in this review assessed live birth as an outcome measure. Outcome measures should also include multiple pregnancy rates and treatment complications.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-03-10 13:49:52 +1300" MODIFIED_BY="Helen E Nagels">
<P>The evidence was limited by small sample sizes for several comparisons, especially for the outcome of live birth. It is also not entirely clear which women are most likely to benefit from the intervention. The 24-month follow up of an RCT included in this meta-analysis (<LINK REF="REF-Johnson-2007" TYPE="REFERENCE">Johnson 2007</LINK>) provided evidence of the effectiveness of lipiodol flushing for women with unexplained infertility. The initial trial showed a positive effect of lipiodol in women with mild endometriosis at six months follow up (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>). The follow-up study showed no enhanced fertility beyond six months in women with endometriosis, but suggested a sustained and consistent enhanced fertility up to 24 months in women with pure unexplained infertility. However, another RCT suggests the most pronounced effect might be apparent in the subgroup of women with endometriosis who have normal patent fallopian tubes (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>). Pregnancy rate and live birth were similar in the follow-up study (<LINK REF="REF-Brent-2006" TYPE="REFERENCE">Brent 2006</LINK>) of the first 100 women receiving lipiodol as a treatment.</P>
<P>Data on adverse events were scanty and in most cases unsuitable for pooling. There needs to be a proper evaluation of complications associated with these procedures.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-02-26 15:35:07 +1300" MODIFIED_BY="Helen E Nagels">
<P>The overall quality of the evidence was low or very low for all comparisons. The main limitations were imprecision, risk of bias and heterogeneity. There were too few studies in any one comparison to evaluate the risk of publication bias. See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>; <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>.</P>
<P>The risk of bias in most of the primary studies was unclear or high for most domains, and only three described satisfactory methods of allocation concealment. Most were unblinded. As noted above, this may not have unduly influenced findings for live birth and pregnancy but could influence the assessment of adverse events. The possibility that increased sexual frequency in a non-blinded trial is a contributory factor to improved fertility is also a possible source for bias in unblinded trials. One trial (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>) collected sexual frequency data and showed that there was no difference in subsequent sexual frequency for those randomised to tubal flushing compared to no treatment.</P>
<P>The source of funding was not stated in nine trials. In the remaining four trials, two were not industry supported (<LINK REF="STD-Lindborg-2009" TYPE="STUDY">Lindborg 2009</LINK>; <LINK REF="STD-Spring-2000" TYPE="STUDY">Spring 2000</LINK>) and in two studies it was stated only that products were supplied free of charge (<LINK REF="STD-Letterie-1990" TYPE="STUDY">Letterie 1990</LINK>; <LINK REF="STD-Rasmussen-1991" TYPE="STUDY">Rasmussen 1991</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-09-25 16:30:47 +1200" MODIFIED_BY="[Empty name]">
<P>We are unaware of any potential biases in our review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-09-25 16:31:20 +1200" MODIFIED_BY="[Empty name]">
<P>Studies comparing OSCM with WSCM have shown a consistent and homogeneous therapeutic effect of oily media in previous meta-analyses (<LINK REF="REF-Vandekerckhove-1993" TYPE="REFERENCE">Vandekerckhove 1993</LINK>). Results from non-randomised studies have also suggested that OSCM tubal flushing increases pregnancy rates and that the pregnancy rate following OSCM tubal flushing exceeds that following WSCM tubal flushing (<LINK REF="REF-Watson-1994" TYPE="REFERENCE">Watson 1994</LINK>). The greatest effect of OSCM tubal flushing occurred in women with unexplained subfertility (<LINK REF="REF-Watson-1994" TYPE="REFERENCE">Watson 1994</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-02-26 00:21:25 +1300" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-02-26 00:20:24 +1300" MODIFIED_BY="[Empty name]">
<P>The evidence suggests that tubal flushing with oil-soluble contrast media may increase the chance of pregnancy and live birth compared to no intervention. Findings for other comparisons were inconclusive due to inconsistency and lack of statistical power. There was no evidence of a difference between any of the groups with respect to adverse events, but such events were poorly reported in most studies.</P>
<P>Tubal flushing with oily media such as lipiodol could represent a simple, less invasive and cost-effective alternative to other modalities of treatment for couples where the woman has normal patent fallopian tubes. Moreover, it is less likely than other options to increase the risk of multiple pregnancy. We suggest that there is a strong argument for adopting this approach as a treatment for unexplained infertility. For safety reasons, we believe it is important for such procedures to be performed only under fluoroscopic control and in women with previously confirmed bilateral tubal patency.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-02-26 00:21:25 +1300" MODIFIED_BY="[Empty name]">
<P>Further robust randomised trials comparing oil-soluble versus water-soluble media or no treatment should be undertaken, with live birth as the primary outcome. Comparative data on adverse events should also be reported. Further scientific research on the OSCM-related improvement in fecundity may clarify its mechanism of working and explain some cases of hitherto 'unexplained' infertility. To investigate the potential advantages of flushing with OSCM a randomised controlled trial comparing this approach with IVF and intrauterine insemination for women with subfertility (either unexplained or with proven appropriately staged endometriosis) seems a logical next step. Future trials should take into account the timing and frequency of intercourse.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-04-15 16:56:46 +1200" MODIFIED_BY="Helen E Nagels">
<P>The authors acknowledge the contributions of these previous authors:</P>
<UL>
<LI>Patrick Vandekerckhove was the primary author of the original review, was involved in trial selection and data extraction of trials for the updated review and critically reviewed the updated review in 2007</LI>
<LI>Tasuku Harada and Richard Lilford were authors of the original review and commented on the updated review in 2007.</LI>
</UL>
<P>We would like to acknowledge members of the editorial office in Auckland for assistance with updates.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-03-10 13:40:18 +1300" MODIFIED_BY="Helen E Nagels">
<P>Neil Johnson and Andrew Watson were investigators in separate RCTs included in this review. Ben Mol is an investigator on ongoing trial <LINK REF="STD-Dreyer-2014" TYPE="STUDY">Dreyer 2014</LINK> investigating oil-based versus water-based contrast media.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-04-15 16:56:03 +1200" MODIFIED_BY="Helen E Nagels">
<P>Lamiya Mohiyiddeen, Anne Hardiman, Cheryl Fitzgerald and Andrew Watson carried out this update in 2015. Andrew Watson was also an author of the original review, was involved in trial selection and data extraction of trials for the updated review and critically appraised previous updates. Neil Johnson conceptualised and carried out the updates of the former review: 'Oil-soluble versus water-soluble media for assessing tubal patency with hysterosalpingography or laparoscopy in subfertile women' (including trial selection and data extraction of trials for the updated reviews), and approved the 2015 update. Ed Hughes was author of the original review, commented on the updated review in 2007, and approved the 2015 update. Ben Mol joined the author group and commented on the 2007 update, and commented on and approved the 2015 update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-02-26 00:23:08 +1300" MODIFIED_BY="[Empty name]">
<P>We have added one new comparison (water-soluble contrast media versus no treatment).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES>
<P>This review was previously known as 'Oil-soluble versus water-soluble media for assessing tubal patency with hysterosalpingography or laparoscopy in subfertile women'.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-04-20 10:44:17 +1200" MODIFIED_BY="Helen E Nagels">
<STUDIES MODIFIED="2015-02-26 01:18:31 +1300" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-02-26 01:14:47 +1300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Fadhli-2006" NAME="Al-Fadhli 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Fadhli R, Sylvestre C, Buckett W, Tulandi T</AU>
<TI>A randomized study of laparoscopic chromopertubation with lipiodol versus saline in infertile woman</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>2</NO>
<PG>505-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alper-1986" MODIFIED="2015-02-26 01:13:21 +1300" MODIFIED_BY="[Empty name]" NAME="Alper 1986" YEAR="1986">
<REFERENCE MODIFIED="2015-02-26 01:13:21 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alper MM, Garner PR, Spence JEH, Quarrington AM</AU>
<TI>Pregnancy rates after hysterosalpingography with oil- and water-soluble contrast media</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1986</YR>
<VL>68</VL>
<PG>6-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boer-1988" NAME="De Boer 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Boer AD, Vemer HM, Willemsen WNP, Saunders FBM</AU>
<TI>Oil or aqueous contrast media for hysterosalpingography: a prospective, randomized, clinical study</TI>
<SO>European Journal of Obstetrics Gynecology and Reproductive Biology</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>65-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2004" MODIFIED="2015-02-26 01:14:16 +1300" MODIFIED_BY="[Empty name]" NAME="Johnson 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-09-11 10:10:36 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Johnson N, Farquhar C, Suckling J, Yu Y, Sadler L, Hadden W</AU>
<TI>The FLUSH Trial - a randomised trial of lipiodol flushing for unexplained subfertility by hysterosalpingography</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology (refereed abstracts of original oral presentations at the Royal Australian and New Zealand College of Obstetricians and Gynaecologists 5th Scientific Meeting, Auckland)</SO>
<YR>2003</YR>
<VL>43</VL>
<PG>406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-16 06:34:52 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson NP, Farquhar CM, Hadden WE, Suckling J, Yu Y, Sadler L</AU>
<TI>The FLUSH Trial - Flushing with lipiodol for unexplained (and endometriosis-related) subfertility by hysterosalpingography: a randomised trial</TI>
<SO>Human Reproduction</SO>
<YR>2004</YR>
<VL>19</VL>
<PG>2043-51</PG>
<IDENTIFIERS MODIFIED="2014-07-16 06:34:52 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-16 06:34:52 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=""/>
<IDENTIFIER MODIFIED="2014-07-16 06:34:40 +1200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-26 01:14:16 +1300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson NP, Kwok R, Stewart AW, Saththianathan M, Hadden WE, Chamley LW</AU>
<TI>Lipiodol fertility enhancement: two-year follow-up of a randomized trial suggests a transient benefit in endometriosis, but a sustained benefit in unexplained infertility</TI>
<SO>Human Reproduction</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>11</NO>
<PG>2857-62</PG>
<IDENTIFIERS MODIFIED="2014-09-01 16:19:48 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-01 16:19:48 +1200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Letterie-1990" NAME="Letterie 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Letterie GS, Rose GS</AU>
<TI>Pregnancy rates after the use of oil-based and water-based contrast media to evaluate tubal patency</TI>
<SO>Southern Medical Journal</SO>
<YR>1990</YR>
<VL>83</VL>
<PG>1402-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindborg-2009" MODIFIED="2015-02-26 01:14:47 +1300" MODIFIED_BY="[Empty name]" NAME="Lindborg 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-02-26 01:14:47 +1300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindborg L, Thorburn J, Bergh C, Strandell A</AU>
<TI>Influence of HyCoSy on spontaneous pregnancy: a randomized controlled trial</TI>
<SO>Human Reproduction</SO>
<YR>2009</YR>
<VL>24</VL>
<PG>1075-9</PG>
<IDENTIFIERS MODIFIED="2012-06-10 06:03:00 +1200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-05-11 21:14:27 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-05-11 21:14:27 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1093/humrep/den485"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindequist-1994" NAME="Lindequist 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindequist S, Rasmussen F, Larsen C</AU>
<TI>Use of iotrolan versus ethiodized poppy-seed oil in hysterosalpingography</TI>
<SO>Radiology</SO>
<YR>1994</YR>
<VL>191</VL>
<PG>513-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nugent-2002" MODIFIED="2014-09-10 16:38:56 +1200" MODIFIED_BY="[Empty name]" NAME="Nugent 2002" YEAR="">
<REFERENCE MODIFIED="2014-09-10 16:38:56 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nugent D, Watson AJ, Killick SR, Balen AH, Rutherford AJ</AU>
<TI>A randomized controlled trial of tubal flushing with lipiodol for unexplained infertility</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<PG>173-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogata-1993" MODIFIED="2014-11-20 16:54:22 +1300" MODIFIED_BY="[Empty name]" NAME="Ogata 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-11-20 16:54:22 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogata R, Nakamura G, Uchiumi Y, Yokoyamay M, Watanabe Y, Nozaki M et al</AU>
<TI>Therapeutic efficacy of hysterosalpingography (HSG) in infertility, a prospective, randomized, clinical study</TI>
<SO>Japanese Journal of Fertility and Sterility</SO>
<YR>1993</YR>
<VL>38</VL>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-1991" NAME="Rasmussen 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindequist S, Justesen P, Larsen C, Rasmussen F</AU>
<TI>Diagnostic quality and complications of hysterosalpingography: oil- versus water-soluble contrast media - a randomized prospective study</TI>
<SO>Radiology</SO>
<YR>1991</YR>
<VL>179</VL>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen F, Lindequist S, Larsen C, Justesen P</AU>
<TI>Therapeutic effect of hysterosalpingography: oil- versus water-soluble contrast media - a randomized prospective study</TI>
<SO>Radiology</SO>
<YR>1991</YR>
<VL>179</VL>
<PG>75-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spring-2000" NAME="Spring 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spring DB, Barkan HE, Pruyn SC</AU>
<TI>Potential therapeutic effects of contrast materials in hysterosalpingography: a prospective randomized clinical trial</TI>
<SO>Radiology</SO>
<YR>2000</YR>
<VL>214</VL>
<PG>53-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-2003" NAME="Steiner 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steiner AZ, Meyer WR, Clark RL, Hartmann KE</AU>
<TI>Oil-soluble contrast during hysterosalpingography in women with proven tubal patency</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>101</VL>
<PG>109-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-1989" NAME="Yang 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang KN, Yeh NG, Pan SB</AU>
<TI>The therapeutic effects of oil-soluble hysterosalpingography contrast medium following water-soluble hysterosalpingography contrast medium</TI>
<SO>Chinese Medical Journal</SO>
<YR>1989</YR>
<VL>44</VL>
<PG>293-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-02-26 01:17:40 +1300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Acton-1988" NAME="Acton 1988" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Acton C, Davitt J, Ryan E</AU>
<TI>Hysterosalpingography in infertility - an experience of 3631 examinations</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1988</YR>
<VL>28</VL>
<PG>127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barwin-1971" NAME="Barwin 1971" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barwin N</AU>
<TI>Hysterosalpingography in infertility</TI>
<SO>Ulster Medical Journal</SO>
<YR>1971</YR>
<VL>41</VL>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Court-2014" MODIFIED="2015-02-26 01:17:01 +1300" MODIFIED_BY="[Empty name]" NAME="Court 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-02-26 01:17:01 +1300" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Court KA, Dare AJ, Weston-Webb M, Hadden WE, Sim RG, Johnson NP</AU>
<TI>Establishment of lipoidal as a fertility treatment - Prospective study of the complete innovative treatment data set</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>2014</YR>
<VL>54</VL>
<PG>13-9</PG>
<IDENTIFIERS MODIFIED="2014-07-02 03:36:28 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-02 03:36:28 +1200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-07-02 03:33:03 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-02 03:33:03 +1200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeCherney-1980" NAME="DeCherney 1980" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeCherney AH, Kort H, Barney JB, DeVore GR</AU>
<TI>Increased pregnancy rate with oil-soluble hysterosalpingography dye</TI>
<SO>Fertility and Sterility</SO>
<YR>1980</YR>
<VL>33</VL>
<PG>407-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gillespie-1965" NAME="Gillespie 1965" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gillespie H</AU>
<TI>The therapeutic aspect of hysterosalpingography</TI>
<SO>British Journal of Radiology</SO>
<YR>1965</YR>
<VL>38</VL>
<PG>301-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mackey-1971" NAME="Mackey 1971" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mackey RA, Glass RH, Olson LE, Vaidya R</AU>
<TI>Pregnancy following hysterosalpingography with oil and water soluble dye</TI>
<SO>Fertility and Sterility</SO>
<YR>1971</YR>
<VL>22</VL>
<PG>504-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perquin-2006" MODIFIED="2015-02-26 01:17:40 +1300" MODIFIED_BY="[Empty name]" NAME="Perquin 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-02-26 01:17:40 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perquin DAM, Dorr PJ, de Craen AJM, Helmerhorst FM</AU>
<TI>Routine use of hysterosalpingography prior to laparoscopy in the fertility workup: a multicentre randomized controlled trial</TI>
<SO>Human Reproduction</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>5</NO>
<PG>1227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-11-29 08:23:30 +1300" MODIFIED_BY="Anne Hardiman">
<IDENTIFIER MODIFIED="2011-11-29 08:23:30 +1300" MODIFIED_BY="Anne Hardiman" TYPE="DOI" VALUE="10.1093/humrep/dei478"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwabe-1983" NAME="Schwabe 1983" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwabe MG, Shapiro SS, Haning RV</AU>
<TI>Hysterosalpingography with oil contrast medium enhances fertility in patients with infertility of unknown etiology</TI>
<SO>Fertility and Sterility</SO>
<YR>1983</YR>
<VL>40</VL>
<PG>604-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-1989" NAME="Wolf 1989" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf G, Fitzpal P</AU>
<TI>Hysterosalpingography with a new contrast medium</TI>
<SO>Fortschritte auf dem Gebiete der Rontgenstrahlem und der Nuklearmedizin - Erganzungsband</SO>
<YR>1989</YR>
<VL>128</VL>
<PG>190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yaegashi-1987" NAME="Yaegashi 1987" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yaegashi N, Kuramoto M, Nakayama C, Nakano M</AU>
<TI>Pregnancy rates after hysterosalpingography - comparing water soluble contrast medium with oily contrast medium</TI>
<SO>Acta Obstetrica et Gynaecologica Japonica</SO>
<YR>1987</YR>
<VL>39</VL>
<PG>1812-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2015-02-26 01:18:31 +1300" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Dreyer-2014" MODIFIED="2015-02-26 01:18:31 +1300" MODIFIED_BY="[Empty name]" NAME="Dreyer 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-02-26 01:18:31 +1300" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Dreyer K</AU>
<TI>Oil-based contrast versus water based contrast media in the diagnosis of tubal patency at Hysterosalpingography. A Randomized Controlled Trial. - H2Olie studie</TI>
<SO>WHO ICTRP</SO>
<YR>http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3270. Accessed 25 November 2014</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-04-20 10:44:17 +1200" MODIFIED_BY="Helen E Nagels">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-14 13:44:15 +1300" MODIFIED_BY="Helen E Nagels">
<REFERENCE ID="REF-Bateman-1987" NAME="Bateman 1987" TYPE="JOURNAL_ARTICLE">
<AU>Bateman BG, Nunley WC, Kitchin JD, Kaizer DL</AU>
<TI>Utility of the 24-hour delay hysterosalpingogram</TI>
<SO>Fertility and Sterility</SO>
<YR>1987</YR>
<VL>47</VL>
<PG>613-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brent-2006" NAME="Brent 2006" TYPE="JOURNAL_ARTICLE">
<AU>Brent K, Hadden WE, Weston-Webb M, Johnson NP</AU>
<TI>After the FLUSH trial: A prospective observational study of lipiodol flushing as an innovative treatment for unexplained and endometriosis-related infertility</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>2006</YR>
<VL>46</VL>
<PG>293-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Capitanio-1991" NAME="Capitanio 1991" TYPE="JOURNAL_ARTICLE">
<AU>Capitanio GL, Ferraiolo A, Croce S, Gazzo R, Anserini P, De Cecco L</AU>
<TI>Transcervical selective salpingography: a diagnostic and therapeutic approach to cases of proximal tubal injection failure</TI>
<SO>Fertility and Sterility</SO>
<YR>1991</YR>
<VL>55</VL>
<PG>1045-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fukui-1999" NAME="Fukui 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fukui A, Fujii S, Yamaguchi E, Kimura H, Sato S, Saito Y</AU>
<TI>NK cell subpopulations and cytotoxicity for infertile patients undergoing in vitro fertilisation</TI>
<SO>American Journal of Reproductive Immunology</SO>
<YR>1999</YR>
<VL>41</VL>
<PG>413-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grant-1971" NAME="Grant 1971" TYPE="JOURNAL_ARTICLE">
<AU>Grant A</AU>
<TI>Infertility surgery of the oviduct</TI>
<SO>Fertility and Sterility</SO>
<YR>1971</YR>
<VL>22</VL>
<PG>495-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1992" NAME="Johnson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Johnson J, Montoya I, Olive D</AU>
<TI>Ethiodol oil contrast medium inhibits macrophage phagocytosis and adherence by altering membrane electronegativity and microviscosity</TI>
<SO>Fertility and Sterility</SO>
<YR>1992</YR>
<VL>58</VL>
<PG>511-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2005-_x0028_c_x0029_" NAME="Johnson 2005 (c)" TYPE="JOURNAL_ARTICLE">
<AU>Johnson NP, Bhattu S, Wagner A, Blake DA, Chamley LW</AU>
<TI>Lipiodol alters murine uterine dendritic cell populations: a potential mechanism for the fertility enhancing effect of lipiodol</TI>
<SO>Fertility and Sterility</SO>
<YR>2005</YR>
<VL>83</VL>
<PG>1814-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerin-1991" NAME="Kerin 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kerin J, Surrey E, Williams D, Daykhovsky L, Grundfest W</AU>
<TI>Falloposcopic observations of endotubal isthmic plugs as a cause of reversible obstruction and their histologic characterisation</TI>
<SO>Journal of Laparoendoscopic Surgery</SO>
<YR>1991</YR>
<VL>1</VL>
<PG>103-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindequist-1991" NAME="Lindequist 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lindequist S, Justesen P, Larsen C, Rasmussen F</AU>
<TI>Diagnostic quality and complications of hysterosalpingography: oil- versus water-soluble contrast media - a randomized prospective study</TI>
<SO>Radiology</SO>
<YR>1991</YR>
<VL>179</VL>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mikulska-1994" NAME="Mikulska 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mikulska D, Kurzawa R, Rozewicka L</AU>
<TI>Morphology of in vitro sperm phagocytosis by rat peritoneal macrophages under influence of oily contrast medium (lipiodol)</TI>
<SO>Acta Europaea Fertilitatis</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>203-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Novy-1988" NAME="Novy 1988" TYPE="JOURNAL_ARTICLE">
<AU>Novy MJ, Thurmond AS, Patton P, Uchida BT, Rosch J</AU>
<TI>Diagnosis of cornual obstruction by transcervical fallopian tube cannulation</TI>
<SO>Fertility and Sterility</SO>
<YR>1988</YR>
<VL>50</VL>
<PG>434-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nunley-1987" NAME="Nunley 1987" TYPE="JOURNAL_ARTICLE">
<AU>Nunley W, Bateman B, Kithchin J, Pope T</AU>
<TI>Intravasation during hysterosalpingography using oil-base contrast medium - a second look</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1987</YR>
<VL>70</VL>
<PG>309-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sawatari-1993" NAME="Sawatari 1993" TYPE="JOURNAL_ARTICLE">
<AU>Sawatari Y, Hori T, Hoshiai H</AU>
<TI>Oily contrast medium as a therapeutic agent for infertility because of mild endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1993</YR>
<VL>59</VL>
<PG>907-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soules-1982" NAME="Soules 1982" TYPE="JOURNAL_ARTICLE">
<AU>Soules MR, Spadoni LR</AU>
<TI>Oil versus aqueous media for hysterosalpingography: a continuing debate based on many opinions and few facts</TI>
<SO>Fertility and Sterility</SO>
<YR>1982</YR>
<VL>28</VL>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sulak-1987" NAME="Sulak 1987" TYPE="JOURNAL_ARTICLE">
<AU>Sulak PJ, Letterie GS, Coddington CC, Hayslip CC, Woodward JE, Klein TA</AU>
<TI>Histology of proximal tubal occlusion</TI>
<SO>Fertility and Sterility</SO>
<YR>1987</YR>
<VL>48</VL>
<PG>437-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thurmond-1990" NAME="Thurmond 1990" TYPE="JOURNAL_ARTICLE">
<AU>Thurmond A, Rosch J</AU>
<TI>Nonsurgical fallopian tube recanalisation for treatment of infertility</TI>
<SO>Radiology</SO>
<YR>1990</YR>
<VL>174</VL>
<PG>371-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vandekerckhove-1993" MODIFIED="2014-09-04 04:59:15 +1200" MODIFIED_BY="[Empty name]" NAME="Vandekerckhove 1993" TYPE="JOURNAL_ARTICLE">
<AU>Vandekerckhove P, O'Donovan P, Lilford R, Vail A, Brosens I, Hughes E</AU>
<TI>Infertility treatment: from cookery to science. The epidemiology of randomised controlled trials</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1993</YR>
<VL>100</VL>
<PG>1005-36</PG>
<IDENTIFIERS MODIFIED="2014-09-04 04:59:15 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-04 04:59:15 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/S0950-3552(96)80005-8"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Watson-1994" NAME="Watson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Watson A, Vandekerckhove P, Lilford R, Vail A, Brosens I, Hughes E</AU>
<TI>A meta-analysis of the therapeutic role of oil soluble contrast media at hysterosalpingography: a surprising result?</TI>
<SO>Fertility and Sterility</SO>
<YR>1994</YR>
<VL>61</VL>
<PG>470-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weir-1951" NAME="Weir 1951" TYPE="JOURNAL_ARTICLE">
<AU>Weir WC, Weir DR</AU>
<TI>Therapeutic value of salpingograms in infertility</TI>
<SO>Fertility and Sterility</SO>
<YR>1951</YR>
<VL>2</VL>
<PG>514-22</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-04-20 10:44:17 +1200" MODIFIED_BY="Helen E Nagels">
<REFERENCE ID="REF-Johnson-2002" MODIFIED="2015-02-26 01:19:51 +1300" MODIFIED_BY="[Empty name]" NAME="Johnson 2002" TYPE="COCHRANE_REVIEW">
<AU>Johnson N, Venderkerckhove P, Watson A, Lilford R, Harada T, Hughes E</AU>
<TI>Tubal flushing for subfertility</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<CY>Auckland</CY>
<IDENTIFIERS MODIFIED="2014-09-04 05:01:14 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-04 05:01:14 +1200" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CD003718"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2005-_x0028_a_x0029_" NAME="Johnson 2005 (a)" TYPE="JOURNAL_ARTICLE">
<AU>Johnson N, Vanderkerckhove P, Watson A, Lilford R, Harada T, Hughes E</AU>
<TI>Tubal flushing for subfertility</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<VL>Art. No.: CD003718.</VL>
<NO>DOI: 10.1002/14651858.</NO>
<PG>CD003718.pub2.</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-2007" MODIFIED="2015-04-20 10:44:17 +1200" MODIFIED_BY="Helen E Nagels" NAME="Johnson 2007" TYPE="COCHRANE_REVIEW">
<AU>Johnson N, Vanderkerchove P, Lilford R, Harada T, Hughes E, Luttjeboer F</AU>
<TI>Tubal flushing for subfertility</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-05-11 01:27:00 +1200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-05-11 01:27:00 +1200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003718.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vandekerckhove-1996" NAME="Vandekerckhove 1996" TYPE="COCHRANE_REVIEW">
<AU>Vandekerckhove P, Watson A, Lilford R, Harada T, Hughes E</AU>
<TI>Oil-soluble versus water-soluble media for assessing tubal patency with hysterosalpingography or laparoscopy in subfertile women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1996</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-02-26 01:27:55 +1300" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-02-26 01:27:55 +1300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-02-26 00:27:22 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Fadhli-2006">
<CHAR_METHODS MODIFIED="2015-02-26 00:25:13 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated random table</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: not mentioned</P>
<P>Analysis: power calculation suggested a requirement for 27 women per contrast group and 39 recruited per group<BR/>Intention-to-treat analysis not performed but possible from the data</P>
<P>Study setting: McGill University Health Center, Montreal, Quebec, Canada</P>
<P>Duration of study: September 2002 to September 2004</P>
<P>Duration of follow up: 6 months</P>
<P>Withdrawals:</P>
<P>88 women recruited and randomised<BR/>1 woman in the lipiodol group excluded (underwent an ovarian cystectomy during the same laparoscopy)<BR/>9 withdrawn after randomisation (4 lost to follow up and 5 had IVF immediately after the laparoscopy with dye sufflation)<BR/>78 women analysed<BR/>
</P>
<P>Source of funding not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:26:20 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 88</P>
<P>Mean age: 32 years (SD 0.6) WSCM; 31 years (SD 0.5) OSCM<BR/>Inclusion criteria: infertile women, duration of infertility not mentioned<BR/>Investigative work-up: early follicular FSH &lt; 10 IU/L, normal semen analysis (criteria not mentioned), ovulatory confirmation by mid-luteal phase progesterone &gt; 25 mmol/L, patent fallopian tubes at HSG. Included women had normal laparoscopic findings or stage I or II endometriosis</P>
<P>Exclusion criteria: iodine allergy</P>
<P>Breakdown by cause of infertility not specified<BR/>Previous fertility treatments not specified<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 00:27:17 +1300" MODIFIED_BY="[Empty name]">
<P>Tubal flushing during laparoscopy, after sufflation with WSCM methylene blue dye: OSCM lipiodol (ultra-fluid; Guerbet/Ezem, Canada, Montreal, Quebec) versus WSCM saline<BR/>A volume of 10 ml of contrast medium was used<BR/>Timing not specified with menstrual cycle<BR/>Co-interventions: excision of endometriosis during the laparoscopy was performed in 20 patients (11 WSCM + OSCM, 9 WSCM)<BR/>Primarily intended as therapeutic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:27:19 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (method of diagnosis not specified)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:27:22 +1300" MODIFIED_BY="[Empty name]">
<P>Unclear whether the assigned treatment was adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 00:30:30 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alper-1986">
<CHAR_METHODS MODIFIED="2015-02-26 00:28:40 +1300" MODIFIED_BY="[Empty name]">
<P>Randomisation: random number table<BR/>Allocation concealment: not mentioned<BR/>Blinding: not mentioned</P>
<P>Trial design: parallel group</P>
<P>Analysis: power calculation not mentioned. Intention-to-treat analysis not performed</P>
<P>Study setting: single-centre; Ottowa Civic Hospital, Ottowa, Canada</P>
<P>Duration of trial: 8 months</P>
<P>Duration of follow up: 6 months</P>
<P>Withdrawals:13 (9.9%) withdrawn after HSG; 12 (9.2%) lost to follow up</P>
<P>131 women recruited and randomised<BR/>106 women analysed<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:29:42 +1300" MODIFIED_BY="[Empty name]">
<P>No of women: 106 analysed</P>
<P>Mean age: mean age 29.3 years (SD 4.6) WSCM; 29.1 years (SD 2.9) OSCM</P>
<P>Cause of infertility:<BR/>Primary or secondary infertility for more than 12 months (mean or range of duration of pre-existing infertility not stated, but duration and proportion of primary to secondary similar in two groups)<BR/>Investigative work-up: semen analysis, PCT, BBT and endometrial biopsy; diagnostic laparoscopy prior to HSG in most women<BR/>Breakdown specified by cause for infertility<BR/>Previous fertility treatments not specified<BR/>Women with bilateral tubal blockage withdrawn after HSG; no other exclusions specified<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 00:30:13 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with OSCM ethiodol (Savage Laboratories, Missouri City, USA) versus WSCM Renographin (ER Squibb &amp; Sons, Princeton, USA)<BR/>A volume of 10 to 20 ml of contrast medium was used<BR/>Timing: any day of menstrual cycle<BR/>No co-interventions<BR/>Primarily intended as diagnostic procedure<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:30:27 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy (diagnosis based on urine hCG or serum beta-hCG plus ultrasound, all the patients had pregnancies confirmed by ultrasound)</P>
<P>Volume of contrast medium used<BR/>Pain during HSG<BR/>Intravasation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:30:30 +1300" MODIFIED_BY="[Empty name]">
<P>Unclear whether the assigned treatment was adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 01:23:57 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Boer-1988">
<CHAR_METHODS MODIFIED="2015-02-26 00:31:14 +1300" MODIFIED_BY="[Empty name]">
<P>Randomisation: not stated</P>
<P>Allocation concealment: not stated</P>
<P>Blinding: not stated</P>
<P>Analysis: not mentioned, intention-to-treat analysis not done</P>
<P>Study setting: St Radboud University Hospital, Nijmegen, Holland</P>
<P>Duration of trial: February 1985 to October 1986</P>
<P>Duration of follow up: 6 months</P>
<P>Withdrawals: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:32:09 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 175</P>
<P>Mean age: 29 years (19 to 44)Primary or secondary infertility for more than six months; mean infertility duration 37 (SD 26.2) months<BR/>Investigative work-up: normal PCT or sperm penetration test, or both, and BBT<BR/>Breakdown by cause for infertility: unexplained only<BR/>Previous fertility treatments not specified other than exclusion for women with previous infertility surgery<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 01:23:57 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with OSCM ethiodol (Guerbet, France) versus WSCM iopamidol (Bracco, Italy)<BR/>A volume of 10 ml contrast medium was used<BR/>Timing: day 6 to 13 of menstrual cycle<BR/>No co-interventions<BR/>Primarily intended as diagnostic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:32:52 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (diagnosis based on ultrasound, although ultrasound criteria not specified)</P>
<P>Quality of visualisation of uterine cavity<BR/>Quality of visualisation of ampullary tubal folds<BR/>Time for contrast medium to disperse from pelvis</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:33:02 +1300" MODIFIED_BY="[Empty name]">
<P>Unclear whether the assigned treatment was adequately concealed prior to allocation<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 00:38:45 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2004">
<CHAR_METHODS MODIFIED="2015-02-26 00:35:31 +1300" MODIFIED_BY="[Empty name]">
<P>Randomisation: two computer-generated random number sequences (A - women with unexplained infertility; B - women with endometriosis in the context of otherwise unexplained infertility)</P>
<P>Allocation concealment: sequentially numbered sealed opaque envelopes</P>
<P>Blinding: no blinding</P>
<P>Trial design: parallel group</P>
<P>Analysis: power calculation and intention-to-treat (ITT) analysis done</P>
<P>Study setting: single-centre, University of Auckland Dept O &amp; G with Fertility Plus, National Women's Hospital, Auckland, New Zealand</P>
<P>Duration of trial: 3 years</P>
<P>Duration of follow up: 6 months</P>
<P>Withdrawals: none</P>
<P>Two separate randomisation schedules were used for the endometriosis and unexplained infertility subpopulations<BR/>Time of randomisation: on same cycle as HSG, usually several days before HSG<BR/>Not blinded</P>
<P>158 women recruited and randomised<BR/>No exclusions before HSG<BR/>No withdrawals<BR/>2 protocol breaches<BR/>3 women lost to follow up<BR/>158 women analysed on ITT basis<BR/>Duration of follow up: 6 months</P>
<P>Single-centre: University of Auckland Dept O &amp; G with Fertility Plus, National Women's Hospital, Auckland, New Zealand</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:37:15 +1300" MODIFIED_BY="[Empty name]">
<P>No of women: 158</P>
<P>Mean age: 33.9 years (SD 2.9) for OSCM; 33.5 years (SD 3.8) for control</P>
<P>Inclusion criteria: unexplained infertility (or endometriosis where fallopian tubes and ovaries unaffected by endometriotic disease) of duration &gt; 12 months, full investigation for the cause complete, age 18 to 39 years, biochemistry as below; confirmed bilateral tubal patency</P>
<P>Cause of infertility: unexplained primary or secondary infertility (primary 54.8% OSCM, 60.0% no treatment) for more than 12 months (mean duration of pre-existing infertility 54.8 months)</P>
<P>Investigative work-up: normal semen analysis by WHO criteria, early follicular FSH &lt; 10 IU/l, ovulatory confirmation by serum progesterone &gt; 25 mmol/l, normal fallopian tubes at laparoscopy and dye insufflation or HSG<BR/>Breakdown by cause for infertility: pure unexplained 61%, endometriosis with normal fallopian tubes and ovaries 39%, all other causes for infertility excluded<BR/>Previous fertility treatments: IVF 34%, IUI 44%, empirical clomiphene 60%, women with endometriosis having previous surgical treatment 60%<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 00:37:32 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with OSCM lipiodol versus no treatment<BR/>Timed after menses but prior to Day 12<BR/>Information sheet on fertile phase of the cycle given to both groups; no other co-interventions<BR/>Primarily intended as therapeutic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:38:41 +1300" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<P>1) clinical pregnancy (diagnosis based on positive pregnancy test and intrauterine gestation sac on ultrasound)</P>
<P>2) live birth</P>
<P>Secondary outcome:</P>
<P>1) miscarriage<BR/>2) ectopic pregnancy<BR/>3) fetal death &gt; 20 weeks<BR/>4) termination<BR/>5) multiple pregnancy<BR/>6) adverse events<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:38:45 +1300" MODIFIED_BY="[Empty name]">
<P>Assigned treatment was clearly adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 00:42:56 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Letterie-1990">
<CHAR_METHODS MODIFIED="2015-02-26 00:40:17 +1300" MODIFIED_BY="[Empty name]">
<P>Randomisation: random number scheme<BR/>Allocation concealment: no mention of this</P>
<P>Blinding: no mention of this</P>
<P>Trial design: parallel group</P>
<P>Analysis: power calculation not mentioned; intention-to-treat analysis not feasible</P>
<P>Study setting:Single-centre; Tripler Army Medical Centre, Honolulu, Hawaii, USA</P>
<P>Duration of study: not mentioned</P>
<P>Duration of follow up: 12 months</P>
<P>Withdrawals: 11 withdrawn after randomisation (8 inadequate follow up and 3 "inadequate coital exposure")<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:42:12 +1300" MODIFIED_BY="[Empty name]">
<P>No of patients: 29</P>
<P>Mean age: 27 (SD 3.5) years OSCM; 25 (SD 4.1) years WSCM (not significant)<BR/>Cause of infertility: unexplained infertility of mean duration 24 (SD 14.5) months OSCM; 28 (SD 13.9) months WSCM; inclusion criterion &gt; 12 months</P>
<P>Inclusion criteria: ovulatory status as documented by biphasic basal body temperature with a 14-day luteal phase; serum progesterone &gt; 3ng/ml or in phase secretory endometrium on biopsy, or both; normal semen analysis; normal pelvic anatomy and bilateral patent tubes</P>
<P>Exclusion criteria: iodine allergy; evidence of endometriosis, tubal disease or pelvic adhesions</P>
<P>Breakdown by cause: not done<BR/>Investigative work-up: normal semen analysis; ovulatory confirmation based on BBT and serum progesterone or secretory phase, or both; normal prolactin, thyroxine and TSH; normal pelvis and bilateral tubal patency at laparoscopy<BR/>Breakdown by cause for infertility: unexplained only<BR/>Previous fertility treatments not specified<BR/>Exclusions specified: where cause for infertility diagnosed; iodine allergy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 00:42:49 +1300" MODIFIED_BY="[Empty name]">
<P>Tubal flushing during laparoscopy, after standard dye studies, with OSCM ethiodol (Savage Laboratories) versus WSCM Conray-60 (Mallinckrodt Inc.)<BR/>A volume of 20 ml of contrast medium was used<BR/>Timing not specified with menstrual cycle<BR/>No co-interventions<BR/>Primarily intended as therapeutic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:42:54 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy (diagnostic criteria not specified)</P>
<P>Ectopic pregnancy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:42:56 +1300" MODIFIED_BY="[Empty name]">
<P>Unclear whether the assigned treatment was adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 01:24:36 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindborg-2009">
<CHAR_METHODS MODIFIED="2015-02-26 00:43:41 +1300" MODIFIED_BY="[Empty name]">
<P>Randomisation: computer-generated randomisation in blocks of 40</P>
<P>Allocation concealment: sealed opaque envelopes used</P>
<P>Blinding: not done</P>
<P>Analysis: intention-to-treat analysis done</P>
<P>Trial design: parallel group</P>
<P>Study setting: Reproductive unit at Sahlgrenska University, Gothenburg, Sweden</P>
<P>Duration of study:December 2001 to May 2006</P>
<P>Duration of follow up: 6 months</P>
<P>Withdrawals: clearly mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:44:04 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 334</P>
<P>Mean age: 31.9 yrs</P>
<P>Inclusions: at least 1 year of subfertility, already scheduled for HyCoSy</P>
<P>Exclusions: &gt; 40 yrs, severe male infertility, severe tubal pathology, suspected anovulation (menstrual period &gt; 35 days)</P>
<P>Breakdown for cause: 63% primary infertility, mean duration of infertility 2.1 yrs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 01:24:36 +1300" MODIFIED_BY="[Empty name]">
<P>All received transvaginal scan prior to use of contrast medium (hydrosalpinx contraindication)</P>
<P>Saline injected into uterine cavity to achieve distension, WSCM (Echovist, Bayer AG) instilled to evaluate tubal patency</P>
<P>Maxiumum 15 ml used</P>
<P>Categorical statement made for each tube (patent, occluded, unclear)</P>
<P>All received oral antibiotic postprocedure</P>
<P>Timing not specified with menstrual cycle</P>
<P>No co-interventions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:44:59 +1300" MODIFIED_BY="[Empty name]">
<P>Primary outcome clinically pregnancy defined sonographically as visible fetal sac within 6 months</P>
<P>Live birth</P>
<P>Miscarriage</P>
<P>Ectopic pregnancy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 00:47:50 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindequist-1994">
<CHAR_METHODS MODIFIED="2015-02-26 00:45:57 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: not stated</P>
<P>Allocation concealment: not mentioned</P>
<P>Blinding: not mentioned</P>
<P>Analysis: no mention of power calculation, intention-to-treat analysis not performed nor possible</P>
<P>Study design: parallel group</P>
<P>Study setting: Odense University Hospital, Odense, Denmark</P>
<P>Duration of study: September 1989 to April 1991</P>
<P>Duration of follow up: 20 to 39 months</P>
<P>Withdrawals: 307 recruited and randomised, 60 patients excluded prior to HSG or lost to follow up, 5 withdrawn after HSG</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:46:58 +1300" MODIFIED_BY="[Empty name]">
<P>No of participants: 242</P>
<P>Mean age: 29.9 yrs OSCM (21 t0 43); 29.5 yrs WSCM (20 to 40)</P>
<P>Inclusions: primary or secondary infertility for more than 12 months; secondary 48 (40%) OSCM, 42 (35%) WSCM</P>
<P>Exclusion criteria: pregnant prior to HSG; HSG declined; technical difficulties leading to unsuccessful HSG; HSG not performed by authors; infertility &lt; 12 months<BR/>Mean duration of pre-existing infertility 41 months OSCM, 40 months WSCM<BR/>Breakdown by cause for infertility not specified<BR/>Previous fertility treatments not specified<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 00:47:23 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with OSCM lipiodol (Laboratories Guerbet, France) versus HSG with WSCM Iotrolan<BR/>A volume of 5 to 10 ml of contrast medium was used<BR/>Timed between end of menses and Day 10<BR/>No co-interventions<BR/>Primarily intended as diagnostic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:47:40 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy (method of diagnosis not specified, but data extracted from Danish Patient Database to complete information with respect to pregnancy)</P>
<P>Image quality<BR/>Pain<BR/>Infection<BR/>Haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:47:50 +1300" MODIFIED_BY="[Empty name]">
<P>Unclear whether the assigned treatment was adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 00:49:38 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nugent-2002">
<CHAR_METHODS MODIFIED="2015-02-26 00:48:37 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: third party sealed envelopes with allocation inside</P>
<P>Allocation concealment: adequate</P>
<P>Blinding: not blinded</P>
<P>Analysis: power calculation specified a requirement for 180 recruits but trial terminated early owing to slow recruitment rate and running out of time<BR/>Intention-to-treat analysis performed</P>
<P>Study setting: Leeds General Infirmary and Princess Royal Hospital, Hull, UK</P>
<P>Duration of study: 10 months</P>
<P>Duration of follow up: 6 months</P>
<P>Withdrawals: nil<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:49:11 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 34</P>
<P>Mean age: 30.6 years (eligibility criterion &lt; 36 years).<BR/>Inclusion criteria: unexplained primary or secondary infertility (proportion of primary and secondary not stated) for more than 12 months (mean duration of pre-existing infertility 49 months)<BR/>Investigative work-up: normal semen analysis by WHO criteria, ovulatory confirmation by serum progesterone or serial scanning, normal fallopian tubes at laparoscopy and dye insufflation or HSG<BR/>Breakdown by cause for infertility: unexplained only, all other causes for infertility excluded<BR/>Previous fertility treatments not specified<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 00:49:30 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with OSCM lipiodol versus no treatment<BR/>Timing with menstrual cycle not specified<BR/>Information sheet on fertile phase of the cycle given to both groups; no other co-interventions<BR/>Primarily intended as therapeutic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:49:36 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy rate (diagnosis based on positive pregnancy test)<BR/>Viable pregnancy (diagnosis based on fetal heart on ultrasound)</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:49:38 +1300" MODIFIED_BY="[Empty name]">
<P>Assigned treatment was clearly adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 00:52:18 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ogata-1993">
<CHAR_METHODS MODIFIED="2015-02-26 00:50:54 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: not stated</P>
<P>Allocation concealment:</P>
<P>Blinding: not mentioned</P>
<P>Analysis: no mention of power calculation. Intention-to-treat analysis not done nor possible</P>
<P>Study setting: University of Kyusyu, Fukuoka, Japan</P>
<P>Study duration: November 1989 to February 1991</P>
<P>Duration of follow up: 4 months</P>
<P>Withdrawals: ? exclusions after randomisation before HSG<BR/>? withdrawals after HSG: only women who had 4 ovulatory cycles were analysed<BR/>? losses to follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:51:47 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 302 randomised (148 versus 154). Those who failed to complete the four ovulatory cycles of observation were excluded, so only 190 were included in analysis (105 versus 85)</P>
<P>Mean age: not specified; said to be similar between the 2 groups<BR/>Inclusion criteria: primary or secondary infertility (proportion not specified) having first visit to infertility clinic; duration of infertility not specified but said to be similar between the 2 groups<BR/>Investigative work-up: not specified, but rate of male infertility and PCT results said to be similar between the 2 groups<BR/>Breakdown by cause for infertility not specified<BR/>Previous fertility treatments not specified<BR/>No exclusion criteria specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 00:52:18 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with oil-soluble contrast medium lipiodol (Ultra-Fluid) versus no HSG (the HSG was delayed for 4 months until after the analysis)<BR/>Volume of contrast medium not specified<BR/>Timing with respect to menstrual cycle not specified<BR/>No co-interventions<BR/>Primarily intended as diagnostic procedure<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:52:05 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy (method of diagnosis not specified)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:52:06 +1300" MODIFIED_BY="[Empty name]">
<P>Unclear whether the assigned treatment was adequately concealed prior to allocation<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 01:26:22 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rasmussen-1991">
<CHAR_METHODS MODIFIED="2015-02-26 00:53:20 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: not stated</P>
<P>Allocation concealment: not stated</P>
<P>Blinding: no mention</P>
<P>Analysis: intention-to-treat analysis not done or not possible, no mention of power calculation</P>
<P>Study setting: Odense University Hospital, Odense, Denmark</P>
<P>Duration of study: 1985 to 1988</P>
<P>Duration of follow up: 9 months</P>
<P>Withdrawals: 507 recruited and randomised, 78 excluded prior to HSG, 31 withdrawn after HSG, 14 lost to follow up (out of 207 in total)<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:53:41 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 398</P>
<P>Mean age: not stated<BR/>Inclusion: primary or secondary infertility for more than 12 months (mean or range of duration of pre-existing infertility not stated)</P>
<P>Exclusion criteria: pregnant prior to HSG; HSG declined; technical difficulties leading to unsuccessful HSG; HSG not performed by authors<BR/>Investigative work-up: not stated<BR/>Breakdown by cause for infertility not specified<BR/>Previous fertility treatments not specified<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 01:26:22 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with OSCM lipiodol (Laboratories Guerbet, France) versus 3 types of WSCM: iohexol (Omnipaque 350, Nycomed, Oslo), Ioxaglate (Hexabrix 320, Laboratoire Guerbet, France), diatrizoate (Urografin, Schering, Berlin). As there were no outcome differences between the 3 groups using WSCM, they were combined in the analysis of results<BR/>A volume of 5 to 10 ml of contrast medium was used<BR/>Timing with menstrual cycle not specified<BR/>No co-interventions<BR/>Primarily intended as diagnostic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:54:30 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy (method of diagnosis not specified)</P>
<P>Other outcomes of this trial (reported image quality, pain, infection, haemorrhage and intravasation) are reported in a separate publication (Lindequist 1991)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:54:32 +1300" MODIFIED_BY="[Empty name]">
<P>Unclear whether the assigned treatment was adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 01:27:13 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spring-2000">
<CHAR_METHODS MODIFIED="2015-02-26 00:55:23 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated random numbers in blocks of 9 at each site<BR/>
</P>
<P>Allocation concealment: adequate<BR/>
</P>
<P>Blinding: not mentioned</P>
<P>Analysis: power calculation suggested a requirement for 257 women per contrast group (achieved for 2 groups and recruitment abandoned for third group owing to difficulty recruiting)<BR/>Intention-to-treat analysis not performed</P>
<P>Study setting: 10 centres co-ordinated by the Kaiser Permanente Medical Care Program Infertility Work Group, California, USA</P>
<P>Duration of study: December 1993 to July 1996</P>
<P>Duration of follow up: 12 months</P>
<P>Withdrawals: 673 recruited and randomised, 7 lost to follow-up</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 00:56:15 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 666</P>
<P>Mean age: 29.3 yrs (SD 4.6) years WSCM; 29.1 yrs (SD 2.9) years OSCM<BR/>Inclusion criteria: primary or secondary infertility (OSCM 35.0%, WSCM 37.1%, WSCM + OSCM 34.8% primary infertility). Mean duration of infertility: OSCM 3.13 (SD 3.03) years, WSCM 3.15 (SD 3.18) years, WSCM + OSCM 3.09 (SD 3.61); eligibility criterion &gt; 12 months<BR/>Investigative work-up: not specified<BR/>Breakdown by cause for infertility not specified<BR/>Previous fertility treatments not specified<BR/>Exclusion criteria: nil</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 01:27:13 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with OSCM ethiodol (Savage Laboratories, Melville, USA) versus WSCM diatrizoate and iodipamide (Bracco Diagnostics, New Brunswick, USA) versus both WSCM and OSCM<BR/>Volume WSCM mean 9.4 (range 2 to 75) ml; OSCM mean 8.6 (range 1 to -55) ml; both - WSCM mean 8.2 (range 1 to 30) ml and OSCM mean 6.0 (range 1 to 20) ml<BR/>Timing with menstrual cycle not specified<BR/>Co-interventions: artificial insemination performed in 25.3% OSCM; 24.6% WSCM; 24.8% WSCM + OSCM<BR/>Primarily intended as diagnostic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 00:57:56 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy (diagnostic criteria not specified)<BR/>Live birth</P>
<P>Miscarriage<BR/>Ectopic pregnancy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 00:57:58 +1300" MODIFIED_BY="[Empty name]">
<P>Assigned treatment was clearly adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 01:01:41 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steiner-2003">
<CHAR_METHODS MODIFIED="2015-02-26 00:59:17 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: computer-generated random numbers<BR/>
</P>
<P>Allocation concealment: not concealed</P>
<P>Analysis: no power calculation, intention to treat analysis not done</P>
<P>Blinding: not done</P>
<P>Study setting: University of Carolina, USA</P>
<P>Duration of study: August 1996 to November 2000</P>
<P>Duration of follow up: 18 months</P>
<P>Withdrawals: 698 recruited, 642 excluded, 3 lost to follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 01:00:09 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 56</P>
<P>Mean age: 32.9 (SD 3.4) years WSCM; 32.6 (SD 3.6) years WSCM + OSCM<BR/>Inclusion criteria: primary or secondary infertility (WSCM 57.5%, WSCM + OSCM 46.7% primary infertility)<BR/>Mean duration of infertility: WSCM 2.9 (SD 3.0) years, WSCM + OSCM 2.8 (SD 2.3) years; eligibility criterion &gt; 12 months</P>
<P>Exclusion criteria: iodine allergy, non-patent tubes, refusal to participate<BR/>Investigative work-up: not specified<BR/>Breakdown by cause for infertility specified but data for subpopulations could not be extracted<BR/>Previous fertility treatments not specified<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 01:01:27 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with WSCM Sinografin (Bracco Diagnostics, New Brunswick, USA) versus WSCM Sinografin + OSCM ethiodol (Savage Laboratories, Melville, USA)<BR/>Timing with menstrual cycle not specified<BR/>Co-interventions: ovulatory medication used in 61.5% WSCM; 53.3% WSCM + OSCM<BR/>Primarily intended as therapeutic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 01:01:37 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy (self report or positive blood or urine pregnancy test)</P>
<P>Time to conception</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 01:01:41 +1300" MODIFIED_BY="[Empty name]">
<P>Allocation was not concealed from physicians; patients were informed of allocation after randomisation before treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-26 01:27:55 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-1989">
<CHAR_METHODS MODIFIED="2015-02-26 01:02:24 +1300" MODIFIED_BY="[Empty name]">
<P>Method of randomisation: not stated.<BR/>
</P>
<P>Allocation concealment: unclear<BR/>Blinding: double blind</P>
<P>Analysis: no mention of power calculation, intention-to-treat analysis not done</P>
<P>Study setting: Mackay Memorial Hospital, Taipei, Japan</P>
<P>Duration of study: October 1986 to March 1987</P>
<P>Duration of follow up: 8 months</P>
<P>Withdrawals: nil</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 01:02:55 +1300" MODIFIED_BY="[Empty name]">
<P>Number of participants: 109</P>
<P>Participant age: range 22 to 44 years; mean age WSCM 30.1 years, WSCM + OSCM 30.0 years<BR/>Inclusion criteria: primary or secondary infertility for more than 12 months (mean or range of duration of pre-existing infertility not stated)</P>
<P>Exclusion criteria: not mentioned<BR/>Investigative work-up: not stated<BR/>Breakdown specified by cause for infertility<BR/>Previous fertility treatments not specified<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 01:27:55 +1300" MODIFIED_BY="[Empty name]">
<P>HSG with WSCM Telebrix Hystero (Laboratories Guerbet) versus WSCM Telebrix Htstero followed by OSCM lipiodol Ultrafluide (Laboratories Guerbet)<BR/>A volume of 10 ml WSCM and 5 ml OSCM were used<BR/>Timing with menstrual cycle not specified<BR/>No co-interventions<BR/>Primarily intended as diagnostic procedure</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 01:03:22 +1300" MODIFIED_BY="[Empty name]">
<P>Pregnancy (method of diagnosis not specified)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-26 01:03:42 +1300" MODIFIED_BY="[Empty name]">
<P>Unclear whether the assigned treatment was adequately concealed prior to allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-02-26 01:06:09 +1300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:04:01 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acton-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:04:01 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised study comparing HSG with OSCM versus WSCM in 420 women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:04:03 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barwin-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:04:03 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised study comparing HSG with OSCM versus WSCM in 248 women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:04:09 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Court-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:04:09 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised observational study looking at pregnancy rates in 100 patients undergoing HSG using OSCM</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:04:12 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeCherney-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:04:12 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised study comparing HSG with OSCM versus WSCM in 339 women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:04:18 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gillespie-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:04:18 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised study comparing HSG with OSCM versus WSCM in 271 women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:04:49 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mackey-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:04:49 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised study of HSG with OSCM versus WSCM versus no treatment in 523 women. (Showed no therapeutic effect of HSG with WSCM (OR 0.87, 95% CI 0.47 to 1.59), but a significantly higher pregnancy rate after HSG with OSCM (OR 1.60, 95%CI 1.09 to 2.35))</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-29 09:20:09 +1300" MODIFIED_BY="Anne Hardiman" STUDY_ID="STD-Perquin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-29 09:20:09 +1300" MODIFIED_BY="Anne Hardiman">
<P>Randomised controlled trial comparing hysterosalpingography prior to laparoscopy and dye in 344 women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:05:08 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwabe-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:05:08 +1300" MODIFIED_BY="[Empty name]">
<P>Described as 'pseudo-randomised' with alternate assignment (thus not a truly randomised trial and therefore excluded), studied HSG with OSCM versus WSCM in 198 women (121 analysed). (Showed no significant difference in the odds of pregnancy for OSCM versus WSCM (OR 2.00, 95% CI 0.74 to 5.45))<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:06:06 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:06:06 +1300" MODIFIED_BY="[Empty name]">
<P>Double-blind RCT of HSG with Iotrolan (WSCM) versus Iohexol versus diatrizoate assessing image quality and pain, but not pregnancy outcomes, in 60 women. A potential therapeutic effect on subsequent pregnancy outcomes could not therefore be studied<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-26 01:06:09 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yaegashi-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-26 01:06:09 +1300" MODIFIED_BY="[Empty name]">
<P>Non-randomised study of HSG with OSCM versus WSCM in 224 women. The details of this study were confirmed after commissioning a translation from the original Japanese publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-02-26 01:07:56 +1300" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-02-26 01:07:56 +1300" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dreyer-2014">
<CHAR_STUDY_NAME MODIFIED="2014-11-25 09:34:52 +1300" MODIFIED_BY="Helen E Nagels">
<P>H2Olie study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-02-26 01:06:28 +1300" MODIFIED_BY="[Empty name]">
<P>Randomised single-blind parallel trial comparing oil-based contrast medium with water-based contrast medium for tubal flushing</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-26 01:07:37 +1300" MODIFIED_BY="[Empty name]">
<P>Inclusion</P>
<P>1. Age between 18 up to and including 39 years</P>
<P>2. Subfertility of at least one year</P>
<P>3. Chlamydia antibody titer (CAT) negative</P>
<P>4. Low risk of tubal pathology according to the medical history</P>
<P>5. Valid indication for HSG in the fertility work-up or before intrauterine insemination treatment</P>
<P>Exclusions</P>
<P>1. Endocrino-pathological diseases as: PCOS, Cushing syndrome, adrenal hyperplasia, hyperprolactinemia, acromegaly, hypothalamic amenorrhea, hypothyroidy, diabetes mellitus type 1</P>
<P>2. Known or high risk for tubal pathology, CAT positive</P>
<P>3. Known contrast (iodine) allergy</P>
<P>4. Male subfertility defined as a post-wash total motile sperm count &lt; 3 x 10<SUP>6</SUP> spermatozoa/ml</P>
<P>5. If not willing or able to sign the consent form</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-26 01:07:44 +1300" MODIFIED_BY="[Empty name]">
<P>Tubal flushing with oil-based contrast medium versus water-based contrast medium</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-26 01:07:56 +1300" MODIFIED_BY="[Empty name]">
<P>Primary: ongoing pregnancy rates</P>
<P>Secondary: live birth rates, miscarriages, ectopic pregnancy and pain scores</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-11-25 09:38:54 +1300" MODIFIED_BY="Helen E Nagels">
<P>1/12/2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-11-25 09:40:01 +1300" MODIFIED_BY="Helen E Nagels">
<P>K Dreyer: k.dreyer@vumc.nl, </P>
<P>Department of Reproductive Medicine VU University Medical Center PK 6Z K180 De Boelelaan 1118, 1081 HV, Amsterdam, The Netherlands, +31 (0)20 4445277</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-11-25 09:45:46 +1300" MODIFIED_BY="Helen E Nagels">
<P>Data collection complete at November 2014; results expected at ESHRE 2015</P>
<P>Funding: VU University Medical Center</P>
<P>NTR3270 accessed 25/11/2014</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-02-26 01:24:42 +1300" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-02-26 01:24:42 +1300" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 00:27:26 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Fadhli-2006">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:18:39 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alper-1986">
<DESCRIPTION>
<P>Random number table used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:19:05 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Boer-1988">
<DESCRIPTION>
<P>Randomisation method not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:19:26 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>Computer-generated random number sequences</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:19:58 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Letterie-1990">
<DESCRIPTION>
<P>Random number scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 01:24:42 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindborg-2009">
<DESCRIPTION>
<P>Computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:45:10 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindequist-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 16:21:21 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nugent-2002">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:20:59 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ogata-1993">
<DESCRIPTION>
<P>No mention of randomisation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:21:20 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:21:44 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spring-2000">
<DESCRIPTION>
<P>Random number scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 01:01:45 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steiner-2003">
<DESCRIPTION>
<P>Computer-generated number scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:22:39 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-1989">
<DESCRIPTION>
<P>The method of randomisation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-09-10 16:44:04 +1200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:18:12 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Fadhli-2006">
<DESCRIPTION>
<P>No mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:18:41 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alper-1986">
<DESCRIPTION>
<P>No mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:19:08 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Boer-1988">
<DESCRIPTION>
<P>No mention of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 16:44:04 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>Allocation concealment: sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:20:00 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Letterie-1990">
<DESCRIPTION>
<P>No mention in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 16:20:46 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindborg-2009">
<DESCRIPTION>
<P>Sealed opaque envelopes envelopes used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:45:07 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindequist-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 16:21:11 +1200" MODIFIED_BY="Anne Hardiman" RESULT="YES" STUDY_ID="STD-Nugent-2002">
<DESCRIPTION>
<P>Third party sealed envelope entry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:21:02 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ogata-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:21:23 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-1991">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:36:20 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spring-2000">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 16:27:46 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steiner-2003">
<DESCRIPTION>
<P>No allocation concealment done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-10-02 21:22:41 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-1989">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-05-11 21:40:57 +1200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-02-26 00:58:05 +1300" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-09-10 16:27:32 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Fadhli-2006">
<DESCRIPTION>
<P>Mentions no blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-02 21:18:43 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alper-1986">
<DESCRIPTION>
<P>No mention of blinding in the text although this could have been possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-02 21:19:10 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Boer-1988">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-26 00:39:00 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>Not possible to blind participants since the treatment involved HSG and control had no treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-02 21:20:02 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Letterie-1990">
<DESCRIPTION>
<P>No mention of this in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-09-10 16:27:01 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindborg-2009">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-02 21:45:02 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindequist-1994">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-02 21:46:10 +1300" MODIFIED_BY="Anne Hardiman" RESULT="UNKNOWN" STUDY_ID="STD-Nugent-2002">
<DESCRIPTION>
<P>No mention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-02 21:21:05 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ogata-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-10-02 21:21:32 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-1991">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-26 00:58:05 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spring-2000">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-09-10 16:26:37 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steiner-2003">
<DESCRIPTION>
<P>Not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-01-14 13:52:29 +1300" MODIFIED_BY="Helen E Nagels" RESULT="YES" STUDY_ID="STD-Yang-1989">
<DESCRIPTION>
<P>States it is double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-09-10 16:52:56 +1200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:18:17 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Fadhli-2006">
<DESCRIPTION>
<P>No mention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:18:55 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alper-1986">
<DESCRIPTION>
<P>No blinding mentioned for the outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:19:12 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Boer-1988">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-09-10 16:52:56 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>No blinding of executor of the assignment or the assessor at follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:20:04 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Letterie-1990">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-09-10 16:36:03 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lindborg-2009">
<DESCRIPTION>
<P>Physicians aware of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:44:57 +1300" MODIFIED_BY="Anne Hardiman" RESULT="NO" STUDY_ID="STD-Lindequist-1994">
<DESCRIPTION>
<P>All examinations and evaluations performed by authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:46:15 +1300" MODIFIED_BY="Anne Hardiman" RESULT="UNKNOWN" STUDY_ID="STD-Nugent-2002">
<DESCRIPTION>
<P>No mention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:21:07 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ogata-1993">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:21:34 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-1991">
<DESCRIPTION>
<P>No mention to suggest this</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-09-10 16:28:13 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spring-2000">
<DESCRIPTION>
<P>Same clinician provided patient details, carried out HSG and reported the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-09-10 16:27:39 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steiner-2003">
<DESCRIPTION>
<P>Clinicians reporting the outcome were aware of the allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-10-02 21:22:46 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-1989">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-02-26 01:01:55 +1300" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-10 16:32:37 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Fadhli-2006">
<DESCRIPTION>
<P>Withdrawals and losses to follow up totalled 11%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-10 16:33:01 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alper-1986">
<DESCRIPTION>
<P>Follow up and withdrawals from the study totalled 19%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-26 00:33:13 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Boer-1988">
<DESCRIPTION>
<P>Rates of loss to follow up and withdrawals from the study were unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-10 16:49:33 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>Losses to follow up and withdrawals totalled 3%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-10 16:34:36 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Letterie-1990">
<DESCRIPTION>
<P>Losses to follow up and withdrawals totalled 28%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-10 16:36:00 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lindborg-2009">
<DESCRIPTION>
<P>Losses to follow up and withdrawals totalled 22%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-10 16:36:37 +1200" MODIFIED_BY="Anne Hardiman" RESULT="NO" STUDY_ID="STD-Lindequist-1994">
<DESCRIPTION>
<P>Losses to follow up and withdrawals totalled 21%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-10 16:40:35 +1200" MODIFIED_BY="Anne Hardiman" RESULT="YES" STUDY_ID="STD-Nugent-2002">
<DESCRIPTION>
<P>All participants apparently included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-26 00:52:31 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ogata-1993">
<DESCRIPTION>
<P>Losses to follow up and withdrawals totalled 37% (102/302)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-26 00:54:44 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-1991">
<DESCRIPTION>
<P>Losses to follow up and withdrawals totalled 9%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-26 00:58:18 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spring-2000">
<DESCRIPTION>
<P>Losses to follow up and withdrawals totalled 1%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-26 01:01:55 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steiner-2003">
<DESCRIPTION>
<P>Losses to follow up and withdrawals totalled 5%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-10 16:38:36 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yang-1989">
<DESCRIPTION>
<P>All participants included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-02-26 00:47:59 +1300" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-24 17:39:31 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Fadhli-2006">
<DESCRIPTION>
<P>Failed to report pain or adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-24 17:39:59 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alper-1986">
<DESCRIPTION>
<P>No selective reporting identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-24 17:40:04 +1200" MODIFIED_BY="Anne Hardiman" RESULT="UNKNOWN" STUDY_ID="STD-De-Boer-1988">
<DESCRIPTION>
<P>Failed to report pain or adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 16:49:29 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>There is no indication that the study reported selected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 00:43:10 +1300" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Letterie-1990">
<DESCRIPTION>
<P>Some aspects like how the pregnancy test was confirmed not clearly mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 00:44:51 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindborg-2009">
<DESCRIPTION>
<P>There is no indication that the study has reported selected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 00:47:59 +1300" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindequist-1994">
<DESCRIPTION>
<P>Pregnancy information from Danish database</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-24 17:40:46 +1200" MODIFIED_BY="Anne Hardiman" RESULT="YES" STUDY_ID="STD-Nugent-2002">
<DESCRIPTION>
<P>No selective reporting identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-24 17:40:49 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ogata-1993">
<DESCRIPTION>
<P>Failed to report pain or adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 16:51:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rasmussen-1991">
<DESCRIPTION>
<P>No selective reporting identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-11 10:50:56 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spring-2000">
<DESCRIPTION>
<P>No selective reporting identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-24 17:41:05 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Steiner-2003">
<DESCRIPTION>
<P>Failed to report pain or adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-24 17:41:11 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-1989">
<DESCRIPTION>
<P>Failed to report pain or adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-02-26 00:58:40 +1300" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:26:23 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Fadhli-2006">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:26:31 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alper-1986">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:26:39 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Boer-1988">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:29:53 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:26:57 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Letterie-1990">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:27:15 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindborg-2009">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:27:20 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lindequist-1994">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:27:25 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nugent-2002">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:27:29 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ogata-1993">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:27:32 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rasmussen-1991">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-26 00:58:40 +1300" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Spring-2000">
<DESCRIPTION>
<P>Interventions not delivered as planned: 25/133 women randomised to receive both WCSM and OSCM did not receive OSCM due to tubal abnormalities shown on WSCM</P>
<P>Groups unequal at baseline: younger women (aged 20 to 24) more likely to be assigned to WSCM, women aged 35 to 39 more likely to be assigend to OSCM</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:27:40 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Steiner-2003">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-25 10:27:44 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yang-1989">
<DESCRIPTION>
<P>No other potential bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-02-26 01:11:50 +1300" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-02-26 01:08:40 +1300" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-09-25 13:47:08 +1200" MODIFIED_BY="[Empty name]">Tubal flushing with oil-soluble contrast media (OSCM) versus no intervention</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Tubal flushing with oil-soluble contrast media (OSCM) versus no intervention </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> Women with subfertility<BR/>
<B>Intervention:</B> Tubal flushing with OSCM versus no intervention<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>No intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OSCM </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>129 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>315 per 1000</P>
<P>(171 to 507)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 3.09</B>
<BR/>(1.39 to 6.91)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>158<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Ongoing pregnancy</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>165 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>414 per 1000</B>
<BR/>(289 to 552)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 3.59 </B>
<BR/>(2.06 to 6.26)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>382<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD COLSPAN="6">
<P>There was no evidence of a difference between any of the interventions in rates of adverse events, but such events were poorly reported in most studies.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk is</B> the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Study was unblinded but this seems unlikely to influence fertility outcomes<BR/>
<SUP>2</SUP> Single study with only 32 events<BR/>
<SUP>3</SUP> Two of the three RCTS did not report methods in adequate detail, and one was at high risk of attrition bias<BR/>
<SUP>4</SUP> Three small RCTs, total of 77 events</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-02-26 01:09:46 +1300" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-09-25 13:48:04 +1200" MODIFIED_BY="[Empty name]">Tubal flushing with water-soluble contrast media (WSCM) versus no intervention</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Tubal flushing with water-soluble contrast media (WSCM) versus no intervention </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> Women with subfertility<BR/>
<B>Intervention:</B> Tubal flushing with WSCM versus no intervention<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>No intervention</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>WSCM </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>205 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>226 per 1000</B>
<BR/>(147 to 330)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.13 </B>
<BR/>(0.67 to 1.91)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>334<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Ongoing pregnancy</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>265 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>291 per 1000</B>
<BR/>(204 to 399)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.14 </B>
<BR/>(0.71 to 1.84)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>334<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD COLSPAN="5">
<P>There was no evidence of a difference between any of the interventions in rates of adverse events, but such events were poorly reported in most studies</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk </B>is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> High risk of attrition bias. Unblinded, but this seems unlikely to influence fertiilty outcomes<BR/>
<SUP>2</SUP> Wide confidence intervals compatible with appreciable benefit, harm or no effect. Low event rates (72 births, 93 pregnancies)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2015-02-26 01:11:00 +1300" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2014-09-25 13:47:56 +1200" MODIFIED_BY="[Empty name]">Tubal flushing with oil-soluble contrast media (OSCM) versus water-soluble contrast media (WSCM)</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Tubal flushing with oil-soluble contrast media (OSCM) versus water-soluble contrast media (WSCM) versus no intervention </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> Women with subfertility<BR/>
<B>Intervention:</B> Tubal flushing with OSCM versus WSCM<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>WSCM</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OSCM </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Live birth</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>931<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>High heterogeneity (I-squared 96%): studies unsuitable for pooling. One study shows benefit for OSCM, the other shows no effect. No conclusions coudl be drawn</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Ongoing pregnancy</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>208 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>274 per 1000</B>
<BR/>(181 to 393)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.44 </B>
<BR/>(0.84 to 2.47)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1454<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD COLSPAN="6">
<P>There was no evidence of a difference between any of the interventions in rates of adverse events, but such events were poorly reported in most studies</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> High heterogeneity (I<SUP>2</SUP> 76%), largely attributable to a single study. No obvious reason for heterogeneity identified<BR/>
<SUP>2</SUP> Wide confidence intervals compatible with substantial benefit from OSCM or with no effect<BR/>
<SUP>3</SUP> No explanation was provided</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2015-02-26 01:11:50 +1300" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2014-09-25 13:47:40 +1200" MODIFIED_BY="[Empty name]">Tubal flushing with oil-soluble plus water-soluble contrast media (OSCM + WSCM) versus WSCM only</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Tubal flushing with oil-soluble plus water-soluble contrast media (OSCM + WSCM) versus water-soluble contrast media (WSCM) </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Population:</B> Women with subfertility<BR/>
<B>Intervention:</B> Tubal flushing with OSCM + WSCM versus WSCM<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>WSCM</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OSCM + WSCM</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Live birth</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>208 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>218 per 1000</B>
<BR/>(144 to 317)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.06 </B>
<BR/>(0.64 to 1.77)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>393<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Ongoing pregnancy</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>317 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>363 per 1000</B>
<BR/>(288 to 444)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>OR 1.23 </B>
<BR/>(0.87 to 1.72)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>633<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse events</B>
</P>
</TD>
<TD COLSPAN="6">
<P>There was no evidence of a difference between any of the interventions in rates of adverse events, but such events were poorly reported in most studies</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk </B>is the median control group risk across studies. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Method of allocation concealment not described<BR/>
<SUP>2</SUP> Wide confidence intervals compatible with substantial benefit, harm or no effect from the intervention. Single study, only 83 events<BR/>
<SUP>3</SUP> Confidence intervals compatible with substantial benefit in the OCSM plus WSCM group, or with no effect; total of 227 events</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-11-20 16:50:51 +1300" MODIFIED_BY="Helen E Nagels">
<COMPARISON ID="CMP-001" MODIFIED="2014-11-20 16:50:51 +1300" MODIFIED_BY="Helen E Nagels" NO="1">
<NAME>OSCM versus no intervention</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.908483517953175" CI_START="1.3861524812735089" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.0945454545454547" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.8393827258019536" LOG_CI_START="0.14181100670669686" LOG_EFFECT_SIZE="0.49059686625432525" METHOD="MH" MODIFIED="2014-11-03 12:27:07 +1300" MODIFIED_BY="Helen E Nagels" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.005836014888603949" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="85" WEIGHT="100.0" Z="2.7568554242245216">
<NAME>Live birth</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>No intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.908483517953175" CI_START="1.3861524812735089" EFFECT_SIZE="3.0945454545454547" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="11" LOG_CI_END="0.8393827258019536" LOG_CI_START="0.14181100670669686" LOG_EFFECT_SIZE="0.49059686625432525" MODIFIED="2014-11-03 12:27:07 +1300" MODIFIED_BY="Helen E Nagels" ORDER="65" O_E="0.0" SE="0.40975708083225315" STUDY_ID="STD-Johnson-2004" TOTAL_1="73" TOTAL_2="85" VAR="0.16790086529216966" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.034904478553882" CI_END="6.2605885305407405" CI_START="2.0586364519429563" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="3.590024478967679" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.7966151612539102" LOG_CI_START="0.3135796584901047" LOG_EFFECT_SIZE="0.5550974098720074" METHOD="MH" MODIFIED="2014-11-20 16:50:51 +1300" MODIFIED_BY="Helen E Nagels" NO="2" P_CHI2="0.596037255841213" P_Q="1.0" P_Z="6.645910661315087E-6" Q="0.0" RANDOM="NO" SCALE="416.98473461471167" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="187" WEIGHT="100.0" Z="4.5047244976218614">
<NAME>Ongoing Pregnancy</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>No intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.629277434323203" CI_START="1.5020537249870154" EFFECT_SIZE="3.1555555555555554" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="14" LOG_CI_END="0.8214661945605104" LOG_CI_START="0.17668546665491522" LOG_EFFECT_SIZE="0.49907583060771277" MODIFIED="2014-11-03 12:28:00 +1300" MODIFIED_BY="Helen E Nagels" ORDER="70" O_E="0.0" SE="0.3787473912878251" STUDY_ID="STD-Johnson-2004" TOTAL_1="73" TOTAL_2="85" VAR="0.14344958640733288" WEIGHT="56.09400027726776"/>
<DICH_DATA CI_END="304.60844900788686" CI_START="0.7785732824300602" EFFECT_SIZE="15.4" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.483741945311952" LOG_CI_START="-0.1087005036390258" LOG_EFFECT_SIZE="1.187520720836463" MODIFIED="2014-07-06 02:59:36 +1200" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="1.5228135273108914" STUDY_ID="STD-Nugent-2002" TOTAL_1="17" TOTAL_2="17" VAR="2.3189610389610387" WEIGHT="2.4423644300618124"/>
<DICH_DATA CI_END="8.515692451332596" CI_START="1.4238793787877537" EFFECT_SIZE="3.482142857142857" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="7" LOG_CI_END="0.9302199682781384" LOG_CI_START="0.15347320043449683" LOG_EFFECT_SIZE="0.5418465843563176" MODIFIED="2014-11-20 16:50:51 +1300" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.45626489638986656" STUDY_ID="STD-Ogata-1993" TOTAL_1="105" TOTAL_2="85" VAR="0.20817765567765567" WEIGHT="41.46363529267043"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.254983025344275" CI_START="0.15987253617606095" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.7962261354508111" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2014-11-03 12:28:31 +1300" MODIFIED_BY="Helen E Nagels" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="23.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="14" WEIGHT="100.0" Z="0.0">
<NAME>Miscarriage per pregnancy</NAME>
<GROUP_LABEL_1>OCSM</GROUP_LABEL_1>
<GROUP_LABEL_2>No intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OCSM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no intervention</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.254983025344275" CI_START="0.15987253617606095" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.796226135450811" LOG_CI_START="-0.7962261354508111" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-11-03 12:28:31 +1300" MODIFIED_BY="Helen E Nagels" ORDER="2804" O_E="0.0" SE="0.9354143466934854" STUDY_ID="STD-Johnson-2004" TOTAL_1="28" TOTAL_2="14" VAR="0.8750000000000001" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2014-09-11 09:56:57 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Procedural pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="41.33791323202438" CI_START="0.06052915023277399" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5818181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.6163485493427674" LOG_CI_START="-1.218035423094018" LOG_EFFECT_SIZE="0.19915656312437466" METHOD="MH" MODIFIED="2014-11-03 12:29:02 +1300" MODIFIED_BY="Helen E Nagels" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.7829845423617816" Q="0.0" RANDOM="NO" SCALE="132.93" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="14" WEIGHT="100.0" Z="0.27543176563545707">
<NAME>Ectopic pregnancy per pregnancy</NAME>
<GROUP_LABEL_1>OCSM</GROUP_LABEL_1>
<GROUP_LABEL_2>No intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no intervention</GRAPH_LABEL_2>
<DICH_DATA CI_END="41.3379132320244" CI_START="0.060529150232773964" EFFECT_SIZE="1.5818181818181818" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6163485493427676" LOG_CI_START="-1.2180354230940182" LOG_EFFECT_SIZE="0.19915656312437466" MODIFIED="2014-11-03 12:29:02 +1300" MODIFIED_BY="Helen E Nagels" ORDER="73" O_E="0.0" SE="1.6649311758363114" STUDY_ID="STD-Johnson-2004" TOTAL_1="28" TOTAL_2="14" VAR="2.7719958202716826" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 15:55:20 +1200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Intravasation</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 15:50:19 +1200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Infection</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Increased by control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Increased with OSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 15:56:13 +1200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Haemorrhage</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 15:56:51 +1200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Long term complications</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-09-25 12:49:16 +1200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>WSCM versus no intervention</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6639767485754775" CI_START="0.7329253082712159" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.104341736694678" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" I2="0.0" I2_Q="100.0" ID="CMP-002.01" LOG_CI_END="0.2211472534235046" LOG_CI_START="-0.13494028164601" LOG_EFFECT_SIZE="0.04310348588874731" METHOD="MH" MODIFIED="2014-09-25 12:49:16 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6351453526298919" Q="4.402017238017063E-33" RANDOM="NO" SCALE="3.8087773375874416" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="166" WEIGHT="100.0" Z="0.47449726053220553">
<NAME>Live birth</NAME>
<GROUP_LABEL_1>WCSM</GROUP_LABEL_1>
<GROUP_LABEL_2>No intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6639767485754775" CI_START="0.7329253082712159" EFFECT_SIZE="1.104341736694678" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="0.2211472534235046" LOG_CI_START="-0.13494028164601" LOG_EFFECT_SIZE="0.04310348588874731" MODIFIED="2012-06-10 06:14:52 +1200" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.20916758076155934" STUDY_ID="STD-Lindborg-2009" TOTAL_1="168" TOTAL_2="166" VAR="0.04375107684164344" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.843304875445006" CI_START="0.7071562333232129" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.141711229946524" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.2655971717753054" LOG_CI_START="-0.15048462612621805" LOG_EFFECT_SIZE="0.05755627282454366" METHOD="MH" MODIFIED="2014-09-25 11:46:28 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5876527722338769" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="168" TOTAL_2="166" WEIGHT="100.0" Z="0.5422405997542147">
<NAME>Ongoing Pregnancy</NAME>
<GROUP_LABEL_1>WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>No intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.843304875445006" CI_START="0.7071562333232129" EFFECT_SIZE="1.141711229946524" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="44" LOG_CI_END="0.2655971717753054" LOG_CI_START="-0.15048462612621805" LOG_EFFECT_SIZE="0.05755627282454366" MODIFIED="2012-06-10 06:10:18 +1200" MODIFIED_BY="Anne Hardiman" ORDER="96" O_E="0.0" SE="0.24440850772547193" STUDY_ID="STD-Lindborg-2009" TOTAL_1="168" TOTAL_2="166" VAR="0.05973551864859208" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.9033681905324946" CI_START="0.35309205816296424" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.46290211436321654" LOG_CI_START="-0.4521120505898043" LOG_EFFECT_SIZE="0.005395031886706144" METHOD="MH" MODIFIED="2014-09-25 11:46:36 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.9815606468120094" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="44" WEIGHT="100.0" Z="0.023112359564252477">
<NAME>Miscarriage per pregnancy</NAME>
<GROUP_LABEL_1>WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>No intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no intervention</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.903368190532494" CI_START="0.3530920581629643" EFFECT_SIZE="1.0125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4629021143632165" LOG_CI_START="-0.45211205058980425" LOG_EFFECT_SIZE="0.005395031886706144" MODIFIED="2014-07-06 03:16:58 +1200" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.5374838498865699" STUDY_ID="STD-Lindborg-2009" TOTAL_1="49" TOTAL_2="44" VAR="0.28888888888888886" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.764001230625977" CI_START="0.05435635967344644" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8958333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.1692040727234332" LOG_CI_START="-1.2647496363154345" LOG_EFFECT_SIZE="-0.047772781796000675" METHOD="MH" MODIFIED="2014-09-25 11:46:43 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9386721049487298" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="44" WEIGHT="100.0" Z="0.07693895854611492">
<NAME>Ectopic pregnancy</NAME>
<GROUP_LABEL_1>WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>No intervention</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no intervention</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.76400123062597" CI_START="0.05435635967344646" EFFECT_SIZE="0.8958333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169204072723433" LOG_CI_START="-1.2647496363154342" LOG_EFFECT_SIZE="-0.047772781796000675" MODIFIED="2014-07-06 03:17:23 +1200" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="1.4297164569546024" STUDY_ID="STD-Lindborg-2009" TOTAL_1="49" TOTAL_2="44" VAR="2.0440891472868215" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2014-09-01 15:59:58 +1200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Procedural pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 16:00:53 +1200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Intravasation</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 16:01:30 +1200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Infection</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 16:02:14 +1200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Haemorrhage</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 16:02:46 +1200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Long term complications</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-10-06 19:21:49 +1300" MODIFIED_BY="[Empty name]" NO="3">
<NAME>OSCM versus WSCM</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="83" EVENTS_2="88" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-09-25 15:55:40 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="371" TOTAL_2="560" WEIGHT="0.0" Z="0.0">
<NAME>Live birth</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.033727137024405" CI_START="1.9744423469324734" EFFECT_SIZE="3.4515570934256057" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" LOG_CI_END="0.7805856662028905" LOG_CI_START="0.29544445700158567" LOG_EFFECT_SIZE="0.538015061602238" ORDER="2806" O_E="0.0" SE="0.28497434777256264" STUDY_ID="STD-Rasmussen-1991" TOTAL_1="98" TOTAL_2="300" VAR="0.08121037888839747" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4042443252671626" CI_START="0.6014653612790137" EFFECT_SIZE="0.9190235690235691" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="54" LOG_CI_END="0.1474426775115858" LOG_CI_START="-0.22078937886205033" LOG_EFFECT_SIZE="-0.03667335067523227" ORDER="2807" O_E="0.0" SE="0.21630133269195032" STUDY_ID="STD-Spring-2000" TOTAL_1="273" TOTAL_2="260" VAR="0.04678626652431378" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.47897284252899" CI_END="2.466550174232323" CI_START="0.8363347502709859" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.4362665574319573" ESTIMABLE="YES" EVENTS_1="161" EVENTS_2="149" I2="75.72664244171344" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.3920899542480289" LOG_CI_START="-0.07761985761268551" LOG_EFFECT_SIZE="0.1572350483176716" METHOD="MH" MODIFIED="2014-09-25 11:47:00 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0024394114958918856" P_Q="1.0" P_Z="0.1894549251164305" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.28132006549794725" TOTALS="YES" TOTAL_1="639" TOTAL_2="815" WEIGHT="100.0" Z="1.312193290530778">
<NAME>Ongoing pregnancy</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WCSM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7966279668352076" CI_START="0.32310465879906736" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.254458155752271" LOG_CI_START="-0.49065677990826" LOG_EFFECT_SIZE="-0.11809931207799451" MODIFIED="2014-06-27 06:47:22 +1200" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.4376842015854128" STUDY_ID="STD-Alper-1986" TOTAL_1="60" TOTAL_2="46" VAR="0.1915674603174603" WEIGHT="16.09817375770483"/>
<DICH_DATA CI_END="3.4435730178219783" CI_START="0.9544822135955361" EFFECT_SIZE="1.8129614438063988" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.5370092962369654" LOG_CI_START="-0.02023216010350771" LOG_EFFECT_SIZE="0.2583885680667288" MODIFIED="2014-09-24 16:16:40 +1200" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.32732638984408946" STUDY_ID="STD-De-Boer-1988" TOTAL_1="87" TOTAL_2="88" VAR="0.10714256548836484" WEIGHT="19.596802758347685"/>
<DICH_DATA CI_END="2.3481405303289953" CI_START="0.6912215052434603" EFFECT_SIZE="1.2740036231884058" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.3707240847902675" LOG_CI_START="-0.16038275857418832" LOG_EFFECT_SIZE="0.10517066310803963" MODIFIED="2014-06-27 06:50:26 +1200" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.31197478881355634" STUDY_ID="STD-Lindequist-1994" TOTAL_1="121" TOTAL_2="121" VAR="0.09732826885526309" WEIGHT="20.10473800559851"/>
<DICH_DATA CI_END="6.033727137024405" CI_START="1.9744423469324734" EFFECT_SIZE="3.4515570934256057" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" LOG_CI_END="0.7805856662028905" LOG_CI_START="0.29544445700158567" LOG_EFFECT_SIZE="0.538015061602238" MODIFIED="2014-09-24 16:27:41 +1200" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.28497434777256264" STUDY_ID="STD-Rasmussen-1991" TOTAL_1="98" TOTAL_2="300" VAR="0.08121037888839747" WEIGHT="20.9985828123027"/>
<DICH_DATA CI_END="1.4042443252671626" CI_START="0.6014653612790137" EFFECT_SIZE="0.9190235690235691" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="54" LOG_CI_END="0.1474426775115858" LOG_CI_START="-0.22078937886205033" LOG_EFFECT_SIZE="-0.03667335067523227" MODIFIED="2014-09-24 16:27:36 +1200" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.21630133269195032" STUDY_ID="STD-Spring-2000" TOTAL_1="273" TOTAL_2="260" VAR="0.04678626652431378" WEIGHT="23.201702666046277"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6426893322286604" CI_START="0.4046228381680325" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8152727272727273" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.2155554368031391" LOG_CI_START="-0.39294960794575573" LOG_EFFECT_SIZE="-0.08869708557130832" METHOD="MH" MODIFIED="2014-09-25 11:47:26 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.567743674205132" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="84" WEIGHT="100.0" Z="0.5713776566147271">
<NAME>Miscarriage per pregnancy</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6426893322286604" CI_START="0.4046228381680325" EFFECT_SIZE="0.8152727272727273" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.2155554368031391" LOG_CI_START="-0.39294960794575573" LOG_EFFECT_SIZE="-0.08869708557130832" ORDER="2824" O_E="0.0" SE="0.3574388754340517" STUDY_ID="STD-Spring-2000" TOTAL_1="74" TOTAL_2="84" VAR="0.1277625496715595" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1242525778822" CI_START="0.09878905997986162" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.4947461368398142" LOG_CI_START="-1.0052911470464263" LOG_EFFECT_SIZE="-0.25527250510330607" METHOD="MH" MODIFIED="2014-09-25 11:47:58 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.5047189262878373" Q="0.0" RANDOM="NO" SCALE="36.97" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="84" WEIGHT="100.0" Z="0.667083307355633">
<NAME>Ectopic pregnancy</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1242525778822" CI_START="0.09878905997986162" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4947461368398142" LOG_CI_START="-1.0052911470464263" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2014-08-26 07:20:39 +1200" MODIFIED_BY="[Empty name]" ORDER="2825" O_E="0.0" SE="0.8811293258590868" STUDY_ID="STD-Spring-2000" TOTAL_1="74" TOTAL_2="84" VAR="0.7763888888888888" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.219610844952031" CI_START="0.07627053919400198" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.12942116348318686" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="281" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.6583462171066085" LOG_CI_START="-1.117643183358867" LOG_EFFECT_SIZE="-0.8879947002327376" METHOD="MH" MODIFIED="2014-09-25 11:48:25 +1200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="3.4902666555299974E-14" Q="0.0" RANDOM="NO" SCALE="24.08" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="103" TOTAL_2="314" WEIGHT="100.0" Z="7.578702925560851">
<NAME>Any postprocedural pain (dichotomous variable)</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.219610844952031" CI_START="0.07627053919400198" EFFECT_SIZE="0.12942116348318686" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="281" LOG_CI_END="-0.6583462171066085" LOG_CI_START="-1.117643183358867" LOG_EFFECT_SIZE="-0.8879947002327376" MODIFIED="2014-07-06 03:40:35 +1200" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.26979331153322705" STUDY_ID="STD-Rasmussen-1991" TOTAL_1="103" TOTAL_2="314" VAR="0.0727884309480649" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.18119156502399775" CI_START="-0.7811915650239982" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2014-09-25 11:48:48 +1200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.22172878864340362" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="1.2219441031404874">
<NAME>Procedural pain (continuous variable)</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1811915650239978" CI_START="-0.7811915650239983" EFFECT_SIZE="-0.30000000000000027" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.2" MODIFIED="2014-07-06 03:41:14 +1200" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="0.9" SD_2="1.6" SE="0.24551041183387842" STUDY_ID="STD-Alper-1986" TOTAL_1="46" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.268795225253578" CI_END="11.223817136429368" CI_START="2.2682168244935528" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="5.045597176141606" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="1.0501405823532857" LOG_CI_START="0.3556845674960815" LOG_EFFECT_SIZE="0.7029125749246836" METHOD="MH" MODIFIED="2014-09-25 11:49:43 +1200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5302548368901365" P_Q="1.0" P_Z="7.258120777741591E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="272" TOTAL_2="496" WEIGHT="100.00000000000001" Z="3.9676618868827145">
<NAME>Intravasation</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="76.33597586106563" CI_START="1.0260234328116786" EFFECT_SIZE="8.85" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.8827292618824303" LOG_CI_START="0.011157279513220465" LOG_EFFECT_SIZE="0.9469432706978255" MODIFIED="2014-07-06 03:30:45 +1200" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="1.0993706468744013" STUDY_ID="STD-Alper-1986" TOTAL_1="46" TOTAL_2="60" VAR="1.2086158192090395" WEIGHT="13.009537016344535"/>
<DICH_DATA CI_END="10.659453924717525" CI_START="0.7143330596333182" EFFECT_SIZE="2.7594202898550724" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0277349567021414" LOG_CI_START="-0.14609925007974098" LOG_EFFECT_SIZE="0.4408178533112002" MODIFIED="2014-07-06 03:30:52 +1200" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.689516023636713" STUDY_ID="STD-Lindequist-1994" TOTAL_1="123" TOTAL_2="122" VAR="0.4754323468517842" WEIGHT="48.54681313139996"/>
<DICH_DATA CI_END="19.928466898616847" CI_START="2.2158337015611833" EFFECT_SIZE="6.645161290322581" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="1.2994738896146378" LOG_CI_START="0.34553716345512386" LOG_EFFECT_SIZE="0.8225055265348807" MODIFIED="2014-07-06 03:31:01 +1200" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.5603471550090494" STUDY_ID="STD-Rasmussen-1991" TOTAL_1="103" TOTAL_2="314" VAR="0.3139889341267356" WEIGHT="38.44364985225552"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.5459487455109446E-32" CI_END="1.6175418690798244" CI_START="0.02728541500097465" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.21008403361344535" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" I2="100.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.20885553093269693" LOG_CI_START="-1.5640694363736836" LOG_EFFECT_SIZE="-0.6776069527204932" METHOD="MH" MODIFIED="2014-09-25 11:50:14 +1200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="1.0" P_Z="0.13408506662374522" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="226" TOTAL_2="436" WEIGHT="100.0" Z="1.4981854816155846">
<NAME>Infection</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-07-06 03:32:04 +1200" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Lindequist-1994" TOTAL_1="123" TOTAL_2="122" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.617541869079825" CI_START="0.027285415000974665" EFFECT_SIZE="0.21008403361344538" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="0.20885553093269704" LOG_CI_START="-1.5640694363736833" LOG_EFFECT_SIZE="-0.6776069527204931" MODIFIED="2014-07-06 03:32:13 +1200" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.0414249019158954" STUDY_ID="STD-Rasmussen-1991" TOTAL_1="103" TOTAL_2="314" VAR="1.0845658263305322" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.021574149963996817" CI_END="1.060132665087419" CI_START="0.39524004853998446" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6473074122918527" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="67" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.02536021631216576" LOG_CI_START="-0.4031390560411163" LOG_EFFECT_SIZE="-0.18888941986447524" METHOD="MH" MODIFIED="2014-09-25 11:50:38 +1200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8832256328940465" P_Q="1.0" P_Z="0.08399400793090803" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="226" TOTAL_2="436" WEIGHT="100.0" Z="1.727967741750591">
<NAME>Haemorrhage</NAME>
<GROUP_LABEL_1>OSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0634016435673495" CI_START="0.38691884759572354" EFFECT_SIZE="0.6414437921287236" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="63" LOG_CI_END="0.026697327213517013" LOG_CI_START="-0.41238011440526623" LOG_EFFECT_SIZE="-0.19284139359587463" MODIFIED="2014-07-06 03:33:28 +1200" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.2579162626752626" STUDY_ID="STD-Lindequist-1994" TOTAL_1="123" TOTAL_2="122" VAR="0.06652079855237505" WEIGHT="95.04594985585379"/>
<DICH_DATA CI_END="6.875763671143386" CI_START="0.08396187345035147" EFFECT_SIZE="0.7598039215686274" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.8373209410106237" LOG_CI_START="-1.0759178795218383" LOG_EFFECT_SIZE="-0.11929846925560729" MODIFIED="2014-07-06 03:36:37 +1200" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="1.123845953865671" STUDY_ID="STD-Rasmussen-1991" TOTAL_1="103" TOTAL_2="314" VAR="1.2630297280202403" WEIGHT="4.954050144146207"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-10-06 19:21:49 +1300" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Long term complications</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Increased with WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Increased with OSCM</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-09-25 11:52:34 +1200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>OSCM + WSCM versus WSCM</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.769861598880492" CI_START="0.6393474420042142" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0637464387464388" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="54" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.24793930636600273" LOG_CI_START="-0.19426306807328136" LOG_EFFECT_SIZE="0.026838119146360653" METHOD="MH" MODIFIED="2014-09-25 11:51:18 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8119524307797975" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="260" WEIGHT="100.0" Z="0.23790802573758751">
<NAME>Live birth</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM+WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.769861598880492" CI_START="0.6393474420042142" EFFECT_SIZE="1.0637464387464388" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="54" LOG_CI_END="0.24793930636600273" LOG_CI_START="-0.19426306807328136" LOG_EFFECT_SIZE="0.026838119146360653" ORDER="2842" O_E="0.0" SE="0.25975186368269165" STUDY_ID="STD-Spring-2000" TOTAL_1="133" TOTAL_2="260" VAR="0.06747103068663163" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.567375722583164" CI_END="1.7216005519726205" CI_START="0.8742454853017283" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2268257863507055" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="129" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.23593239322806142" LOG_CI_START="-0.05836660175661813" LOG_EFFECT_SIZE="0.08878289573572164" METHOD="MH" MODIFIED="2014-09-25 11:51:25 +1200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9038586226400634" P_Q="1.0" P_Z="0.23698853001689157" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="248" TOTAL_2="385" WEIGHT="100.0" Z="1.1825475523234303">
<NAME>Ongoing Pregnancy</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours OSCM+WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9768870225781714" CI_START="0.6160359769167748" EFFECT_SIZE="1.565217391304348" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.5995432535035032" LOG_CI_START="-0.21039392400411447" LOG_EFFECT_SIZE="0.1945746647496944" MODIFIED="2014-09-24 17:07:19 +1200" MODIFIED_BY="[Empty name]" ORDER="2844" O_E="0.0" SE="0.4757611073216637" STUDY_ID="STD-Al_x002d_Fadhli-2006" TOTAL_1="39" TOTAL_2="39" VAR="0.2263486312399356" WEIGHT="11.793005112359328"/>
<DICH_DATA CI_END="1.7232994064190401" CI_START="0.7121691932703307" EFFECT_SIZE="1.1078270388615217" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="84" LOG_CI_END="0.236360738422615" LOG_CI_START="-0.14741681679216753" LOG_EFFECT_SIZE="0.044471960815223734" MODIFIED="2014-09-24 17:07:26 +1200" MODIFIED_BY="[Empty name]" ORDER="2846" O_E="0.0" SE="0.22543283566270003" STUDY_ID="STD-Spring-2000" TOTAL_1="133" TOTAL_2="260" VAR="0.050819963394925914" WEIGHT="61.97492298343764"/>
<DICH_DATA CI_END="4.270333357139116" CI_START="0.46839530180676053" EFFECT_SIZE="1.4142857142857144" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.6304617788927163" LOG_CI_START="-0.3293874697261301" LOG_EFFECT_SIZE="0.15053715458329311" MODIFIED="2014-09-24 17:07:20 +1200" MODIFIED_BY="[Empty name]" ORDER="2847" O_E="0.0" SE="0.5638201999691195" STUDY_ID="STD-Steiner-2003" TOTAL_1="28" TOTAL_2="25" VAR="0.3178932178932179" WEIGHT="8.803637942778497"/>
<DICH_DATA CI_END="2.9427422148830567" CI_START="0.5977803847412807" EFFECT_SIZE="1.3263157894736841" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.4687522194365824" LOG_CI_START="-0.22345833977915214" LOG_EFFECT_SIZE="0.1226469398287151" MODIFIED="2014-09-24 17:07:25 +1200" MODIFIED_BY="[Empty name]" ORDER="2848" O_E="0.0" SE="0.40660790898085236" STUDY_ID="STD-Yang-1989" TOTAL_1="48" TOTAL_2="61" VAR="0.1653299916457811" WEIGHT="17.428433961424535"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.4757302034953477" CI_START="0.5267200147586969" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1419354838709677" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.39370331501794" LOG_CI_START="-0.2784201786349097" LOG_EFFECT_SIZE="0.05764156819151511" METHOD="MH" MODIFIED="2014-09-25 11:52:04 +1200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7367392637940251" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="84" WEIGHT="100.0" Z="0.33617452368397865">
<NAME>Miscarriage per pregnancy</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM + WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4757302034953477" CI_START="0.5267200147586969" EFFECT_SIZE="1.1419354838709677" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" LOG_CI_END="0.39370331501794" LOG_CI_START="-0.2784201786349097" LOG_EFFECT_SIZE="0.05764156819151511" ORDER="2858" O_E="0.0" SE="0.39480866723663577" STUDY_ID="STD-Spring-2000" TOTAL_1="46" TOTAL_2="84" VAR="0.15587388372516858" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.381664805164323" CI_START="0.05365039630206386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.6416391512175001" LOG_CI_START="-1.2704270656614256" LOG_EFFECT_SIZE="-0.31439395722196267" METHOD="MH" MODIFIED="2014-09-25 11:52:34 +1200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.519225838147851" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="274" WEIGHT="100.00000000000001" Z="0.6445392190631355">
<NAME>Ectopic pregnancy</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OSCM + WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours WSCM</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2859" O_E="0.0" SE="0.0" STUDY_ID="STD-Letterie-1990" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.381664805164323" CI_START="0.05365039630206386" EFFECT_SIZE="0.48484848484848486" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.6416391512175001" LOG_CI_START="-1.2704270656614256" LOG_EFFECT_SIZE="-0.31439395722196267" ORDER="2860" O_E="0.0" SE="1.1231571606751023" STUDY_ID="STD-Spring-2000" TOTAL_1="133" TOTAL_2="260" VAR="1.2614820075757576" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2014-09-01 16:09:29 +1200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Procedural pain</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Increased with WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Increased with both</GRAPH_LABEL_2>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 16:09:46 +1200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Intravasation</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Increased with WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Increased with both</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 16:10:19 +1200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Infection</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Increased with WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Increased with both</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 16:10:37 +1200" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Haemorrhage</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Increased with WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Increased with both</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" MODIFIED="2014-09-01 16:10:58 +1200" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Long term complications</NAME>
<GROUP_LABEL_1>OSCM + WSCM</GROUP_LABEL_1>
<GROUP_LABEL_2>WSCM</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours WSCM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours both</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-02-26 01:24:43 +1300" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-02-26 01:24:43 +1300" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-02-26 01:24:43 +1300" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU8AAALbCAIAAAD1sJVtAAAkDUlEQVR42u3dsY7dxtnG8QUCBCm2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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-10-24 15:08:59 +1300" MODIFIED_BY="Helen E Nagels" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlAAAAK8CAYAAAAgZIG8AABad0lEQVR42u2df0Rf7///P8zMzMyY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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2015-02-26 01:24:43 +1300" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 OSCM versus no intervention, outcome: 1.1 Live birth.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxoAAACQCAMAAAC4Xe1DAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2015-02-26 01:24:43 +1300" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 WSCM versus no intervention, outcome: 2.1 Live birth.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAxwAAACQCAMAAAC1Q50EAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2015-02-26 01:24:43 +1300" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-003.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 OSCM versus WSCM, outcome: 3.1 Live birth.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsgAAABwCAMAAAA0c3Z1AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2015-02-26 01:24:43 +1300" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-004.01" SETTINGS="SHOW_ROB_TABLE:NO;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 OSCM + WSCM versus WSCM, outcome: 4.1 Live birth.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAx0AAACQCAMAAABagfY6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-10-24 15:44:50 +1300" MODIFIED_BY="Helen E Nagels">
<APPENDIX ID="APP-01" MODIFIED="2014-09-25 14:06:13 +1200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-08-26 05:36:29 +1200" MODIFIED_BY="[Empty name]">MDSG search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-25 14:06:13 +1200" MODIFIED_BY="[Empty name]">
<P>Menstrual Disorders and Subfertility database search strategy for NJ212 11.01.11- limited to 2007 until present.</P>
<P>Keywords CONTAINS "fertility" or "subfertility" or "infertility" or "hysterosalpingogram" or "hysterosalpingography" or "laparoscopic chromopertubation" or "laparoscopy" or "Fallopian-Tube-Patency-Tests" or "tubal flushing" or "tubal patency" or "flushing media" or Title CONTAINS "fertility" or "subfertility" or "infertility" or "hysterosalpingogram" or "hysterosalpingography" or "laparoscopic chromopertubation" or "laparoscopy" or "Fallopian-Tube-Patency-Tests" or "tubal flushing" or "tubal patency" or "flushing media"</P>
<P>AND</P>
<P>Keywords CONTAINS "oil" or "oil-soluble contrast" or "Water-Soluble Contrast" or "Aqueous" or "lipiodol" or "lipiodol flushing" or "lipiodol-pingyangmycin emulsion" or "Contrast-Media" or "Flushing" or Title CONTAINS "oil" or "oil-soluble contrast" or "Water-Soluble Contrast" or "Aqueous" or "lipiodol" or "lipiodol flushing" or "lipiodol-pingyangmycin emulsion" or "Contrast-Media" or "Flushing"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-07-10 16:15:24 +1200" MODIFIED_BY="Helen E Nagels" NO="2">
<TITLE MODIFIED="2014-07-10 16:13:18 +1200" MODIFIED_BY="Helen E Nagels">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-10 16:15:24 +1200" MODIFIED_BY="Helen E Nagels">
<P>1 HYSTEROSALPINGOGRAPHY/ or hysterosalpingog$.tw. (4547)<BR/>2 salpingog$.tw. (181)<BR/>3 HSG.tw. (1046)<BR/>4 laparoscop$.tw. (82655)<BR/>5 LAPAROSCOPY/ (59726)<BR/>6 Fallopian Tube Patency Tests/ (601)<BR/>7 (tubal adj flush$).tw. (23)<BR/>8 (tub$ adj patency).tw. (833)<BR/>9 chromopertub$.tw. (99)<BR/>10 fertili$.tw. (105699)<BR/>11 or/1-10 (199539)<BR/>12 OILS/ (9645)<BR/>13 oil$.tw. (97949)<BR/>14 Ethiodized Oil/ (529)<BR/>15 ethiodol.tw. (119)<BR/>16 iotrolan.tw. (199)<BR/>17 poppy.tw. (766)<BR/>18 Iodized Oil/ (2894)<BR/>19 IODIPAMIDE/ (620)<BR/>20 WATER/ (111567)<BR/>21 Contrast Media/ (65942)<BR/>22 contrast medi$.tw. (20603)<BR/>23 (water adj soluble).tw. (31267)<BR/>24 (oil adj soluble).tw. (339)<BR/>25 aqueous.tw. (131938)<BR/>26 lipiodol.tw. (2225)<BR/>27 OSCM.tw. (12)<BR/>28 WSCM.tw. (15)<BR/>29 or/12-28 (419392)<BR/>30 11 and 29 (3180)<BR/>31 randomized controlled trial.pt. (376220)<BR/>32 controlled clinical trial.pt. (88548)<BR/>33 randomized.ab. (296250)<BR/>34 placebo.tw. (159087)<BR/>35 clinical trials as topic.sh. (170403)<BR/>36 randomly.ab. (214362)<BR/>37 trial.ti. (127538)<BR/>38 (crossover or cross-over or cross over).tw. (60957)<BR/>39 or/31-38 (929229)<BR/>40 exp animals/ not humans.sh. (3951224)<BR/>41 39 not 40 (856083)<BR/>42 30 and 41 (133)<BR/>43 (201308$ or 201309$ or 201310$ or 201311$ or 201312$).ed. (411662)<BR/>44 2014$.ed. (453961)<BR/>45 2014$.dp. (442079)<BR/>46 43 or 44 or 45 (1207235)<BR/>47 42 and 46 (9)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-07-10 16:15:46 +1200" MODIFIED_BY="Helen E Nagels" NO="3">
<TITLE MODIFIED="2014-07-10 16:13:36 +1200" MODIFIED_BY="Helen E Nagels">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-10 16:15:46 +1200" MODIFIED_BY="Helen E Nagels">
<P>1 exp HYSTEROSALPINGOGRAPHY/ (4376)<BR/>2 hysterosalpingog$.tw. (2694)<BR/>3 salpingog$.tw. (227)<BR/>4 HSG.tw. (1452)<BR/>5 laparoscop$.tw. (117162)<BR/>6 exp LAPAROSCOPY/ (99372)<BR/>7 (tubal adj flush$).tw. (27)<BR/>8 (tub$ adj patency).tw. (994)<BR/>9 chromopertub$.tw. (130)<BR/>10 fertili$.tw. (119535)<BR/>11 or/1-10 (258375)<BR/>12 exp oil/ (14298)<BR/>13 oil$.tw. (124170)<BR/>14 exp ethiodized oil/ (577)<BR/>15 ethiodol.tw. (242)<BR/>16 iotrolan.tw. (222)<BR/>17 poppy.tw. (908)<BR/>18 exp ethiodized oil/ (577)<BR/>19 exp adipiodone/ (591)<BR/>20 exp WATER/ (277044)<BR/>21 IODIPAMIDE.tw. (134)<BR/>22 water.tw. (576375)<BR/>23 exp contrast medium/ (117267)<BR/>24 contrast medi$.tw. (22787)<BR/>25 (water adj soluble).tw. (35678)<BR/>26 (oil adj soluble).tw. (386)<BR/>27 aqueous.tw. (155448)<BR/>28 lipiodol.tw. (3652)<BR/>29 OSCM.tw. (16)<BR/>30 WSCM.tw. (16)<BR/>31 or/12-30 (987131)<BR/>32 11 and 31 (10395)<BR/>33 Clinical Trial/ (831601)<BR/>34 Randomized Controlled Trial/ (343448)<BR/>35 exp randomization/ (62313)<BR/>36 Single Blind Procedure/ (18367)<BR/>37 Double Blind Procedure/ (113645)<BR/>38 Crossover Procedure/ (39147)<BR/>39 Placebo/ (240637)<BR/>40 Randomi?ed controlled trial$.tw. (98971)<BR/>41 Rct.tw. (13930)<BR/>42 random allocation.tw. (1308)<BR/>43 randomly allocated.tw. (20183)<BR/>44 allocated randomly.tw. (1921)<BR/>45 (allocated adj2 random).tw. (712)<BR/>46 Single blind$.tw. (14252)<BR/>47 Double blind$.tw. (140404)<BR/>48 ((treble or triple) adj blind$).tw. (370)<BR/>49 placebo$.tw. (197255)<BR/>50 prospective study/ (252453)<BR/>51 or/33-50 (1358985)<BR/>52 case study/ (26347)<BR/>53 case report.tw. (258214)<BR/>54 abstract report/ or letter/ (891787)<BR/>55 or/52-54 (1170729)<BR/>56 51 not 55 (1321392)<BR/>57 32 and 56 (463)<BR/>58 (201308$ or 201309$ or 201310$ or 201311$ or 201312$).em. (109480)<BR/>59 2014$.em. (812650)<BR/>60 2014$.dp. (52878)<BR/>61 58 or 59 or 60 (924299)<BR/>62 57 and 61 (31)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-07-10 16:16:03 +1200" MODIFIED_BY="Helen E Nagels" NO="4">
<TITLE MODIFIED="2014-07-10 16:13:50 +1200" MODIFIED_BY="Helen E Nagels">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-10 16:16:03 +1200" MODIFIED_BY="Helen E Nagels">
<P>1 HYSTEROSALPINGOGRAPHY/ or hysterosalpingog$.tw. (171)<BR/>2 salpingog$.tw. (7)<BR/>3 HSG.tw. (75)<BR/>4 laparoscop$.tw. (5936)<BR/>5 LAPAROSCOPY/ (2714)<BR/>6 Fallopian Tube Patency Tests/ (28)<BR/>7 (tubal adj flush$).tw. (4)<BR/>8 (tub$ adj patency).tw. (60)<BR/>9 chromopertub$.tw. (11)<BR/>10 fertili$.tw. (2691)<BR/>11 or/1-10 (8766)<BR/>12 OILS/ (107)<BR/>13 oil$.tw. (4703)<BR/>14 Ethiodized Oil/ (24)<BR/>15 ethiodol.tw. (2)<BR/>16 iotrolan.tw. (37)<BR/>17 poppy.tw. (18)<BR/>18 Iodized Oil/ (115)<BR/>19 IODIPAMIDE/ (18)<BR/>20 WATER/ (1487)<BR/>21 Contrast Media/ (2127)<BR/>22 contrast medi$.tw. (1449)<BR/>23 (water adj soluble).tw. (467)<BR/>24 (oil adj soluble).tw. (20)<BR/>25 aqueous.tw. (2238)<BR/>26 lipiodol.tw. (155)<BR/>27 OSCM.tw. (4)<BR/>28 WSCM.tw. (4)<BR/>29 or/12-28 (11564)<BR/>30 11 and 29 (106)<BR/>31 limit 30 to yr="2013 -Current" (5)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-07-10 16:16:35 +1200" MODIFIED_BY="Helen E Nagels" NO="5">
<TITLE MODIFIED="2014-07-10 16:16:22 +1200" MODIFIED_BY="Helen E Nagels">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-10 16:16:35 +1200" MODIFIED_BY="Helen E Nagels">
<P>1 exp Fertility Enhancement/ or exp Infertility/ (1731)<BR/>2 hysterosalpingog$.tw. (3)<BR/>3 HSG.tw. (22)<BR/>4 laparoscop$.tw. (299)<BR/>5 (tubal adj flush$).tw. (0)<BR/>6 (tub$ adj patency).tw. (2)<BR/>7 chromopertub$.tw. (0)<BR/>8 fertili$.tw. (7390)<BR/>9 or/1-8 (8828)<BR/>10 oil$.tw. (3378)<BR/>11 Ethiodized Oil.tw. (0)<BR/>12 ethiodol.tw. (0)<BR/>13 iotrolan.tw. (0)<BR/>14 poppy.tw. (81)<BR/>15 Iodized Oil$.tw. (3)<BR/>16 IODIPAMIDE.tw. (0)<BR/>17 WATER.tw. (27085)<BR/>18 Contrast Medi$.tw. (95)<BR/>19 aqueous.tw. (503)<BR/>20 lipiodol.tw. (8)<BR/>21 OSCM.tw. (1)<BR/>22 WSCM.tw. (0)<BR/>23 or/10-22 (30736)<BR/>24 9 and 23 (90)<BR/>25 limit 24 to yr="2013 -Current" (10)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-10-24 15:44:30 +1300" MODIFIED_BY="Helen E Nagels" NO="6">
<TITLE MODIFIED="2014-10-24 15:44:30 +1300" MODIFIED_BY="Helen E Nagels">Biological abstracts</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-10 16:18:40 +1200" MODIFIED_BY="Helen E Nagels">
<P>1.HYSTEROSALPINGOGRAPHY/ or hysterosalpingography.mp. or hysterosalpingog$.tw.<BR/>2. salpingog$.tw.<BR/>3. HSG.tw.<BR/>4. laparoscopy adj3 dye).tw.<BR/>5. LAPAROSCOPY/<BR/>6. Fallopian Tube Patency Tests/<BR/>7. tubal adj flush$).mp. [mp=ti, kw, ab, bc, bt, bo, sh, hw, tn, ot, dm,mf, rw]<BR/>8. tub$ adj patency).tw.<BR/>9. or/1-8<BR/>10. OILS/<BR/>11. Ethiodized Oil/<BR/>12. Iodized Oil/<BR/>13. IODIPAMIDE/<BR/>14. WATER/<BR/>15. Contrast Media/<BR/>16. water adj soluble).tw.<BR/>17. oil adj soluble).tw.<BR/>18. lipiodol.tw.<BR/>19. OSCM.tw.<BR/>20. WSCM.tw.<BR/>21. Or/10-20<BR/>22. 9 and 21<BR/>23. exp clinical trials/<BR/>24. exp research design/<BR/>25. clinical trial.pt.<BR/>26. randomised controlled trial.pt.<BR/>27. (singl$ or doubl$ or trebl$ or tripl$).tw.<BR/>28. (mask$ or Blind$).tw.<BR/>29. 27 and 28<BR/>30. placebos/ or placebo.tw.<BR/>31. 23 or 24 or 25 or 26 or 29 or 30<BR/>32. 22 and 31</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_3" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="3">
<FLOWCHARTBOX TEXT="&lt;p&gt;13 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;13 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 studies included in previous published version of this review (Johnson 2007)&lt;/p&gt;" WIDTH="150"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;12 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;207 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;207 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;211 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;193 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;11 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>